Information on EC 3.1.3.48 - protein-tyrosine-phosphatase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY
3.1.3.48
-
RECOMMENDED NAME
GeneOntology No.
protein-tyrosine-phosphatase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism, transition state of reaction, kinetic isotope effects, overview
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism, role of residue 182
P18031
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
thermodynamic parameters
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism, kinetic isotope effects
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
comparison of kinetic properties of different transmembrane and cytosolic isozymes
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
overview on mechanism and transition state
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism, overview
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism, features required for substrate
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
activation mechanism
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
in addition to active site, enzyme has a low-affinity noncatalytic aryl phosphate-binding site
P18031
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
H148 acts as a general acid catalyst, D115 assists the protonation of the leaving group of a substrate, and D76 and D112 are involved in binding of magnesium ions
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
conformation of active site is favorable for phosphotyrosine binding. Interaction of D115 and R13 to stabilize the conformation of the active cavity. A41 and G45 form a noncharged surface around the active cavity, which is surrounded by a flexible wall made of the loop region from F40 to T48
P39155
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
arrangement of two metal ions, a phosphate ion, and amino acid residues in the catalytic site is identical to that of PS/Tpases
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
motif H74C(X)5R81 is involved in catalysis
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
ping-pong mechanism, catalysis proceeds through a two-step mechanism involving a phosphocysteine intermediate. In the first step, a nucleophilic cysteine thiolate attacks the phosphate ester moiety of the substrate, resulting in formation of a phosphoenzyme intermediate with release of the peptidyl tyrosine. The second step occurs via attack of water on the phosphoenzyme intermediate, and yields the final products inorganic phosphate and the regenerated enzyme. The central binding site for the substrate is the P-loop, a region at the bottom of a pocket that includes the nucleophilic cysteine and backbone amide groups oriented in a horseshoe fashion, catalytic cycle, detailed overview
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism of the dephosphorylation catalysed by MptpA
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
mechanism
-
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
hydrolysis of phosphoric ester
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
protein-tyrosine-phosphate phosphohydrolase
Dephosphorylates O-phosphotyrosine groups in phosphoproteins, such as the products of EC 2.7.10.2, non-specific protein-tyrosine kinase.
SYNONYMS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
70Z-SHP
-
-
-
-
acid phosphatase ortholog
-
the enzyme share the conserved RHGXRXP motif characteristic of the histidine acid phosphatase family
acid tyrosine phosphatase
-
-
alpha-PTP-PEST
-
-
BDP
Q99952
-
Brain-derived phosphatase
-
-
-
-
BVP
-
-
-
-
CAPTPase
-
-
CAPTPase
Q9S427
-
CD148
-
-
CD148 antigen
-
-
-
-
CD45
-
-
-
-
CD45
-
-
CD45 antigen
-
-
-
-
CD45 protein tyrosine phosphatase
-
-
Cdc25 phosphatase
-
-
Cdc25-like protein
-
-
-
-
Cdc25A
-
-
Cdc25A
P30304
-
Cdc25B
P30305
-
Cdc25B phosphatase
-
-
Cdc25C
-
-
Cdc25C
P30307
-
CDK2-associated dual specificity phosphatase
-
-
-
-
Ch-1PTPase
-
-
-
-
chick retinal tyrosine phosphatase-2
-
-
cold-active protein tyrosine phosphatase
Q9S427
-
CPTP1
-
-
-
-
Cryp-2
-
-
CRYP-2/PTPRO
-
-
CRYP-2/receptor-type tyrosine-protein phosphatase O
-
-
cysteine-dependent protein tyrosine phosphatase
Homo sapiens, Yersinia enterolytica
-
-
cyt-PTPepsilon
-
non-receptor-type isoform of PTPepsilon
DEP-1
-
-
DEP-1
Q12913
-
DLAR
-
-
-
-
dPTP61F
-
dPTP61F plays a central role in counteracting PTK-mediated signaling pathways as well as in regulating actin reorganization and remodeling through tyrosine dephosphorylation of critical substrates in Drosophila
DSP18
-
-
dual specificity phosphatase
-
-
dual specificity phosphatase
P30305, P30307
-
Dual specificity phosphatase Cdc25A
-
-
-
-
Dual specificity phosphatase Cdc25B
-
-
-
-
Dual specificity phosphatase Cdc25C
-
-
-
-
Dual specificity protein phosphatase hVH1
-
-
-
-
Dual specificity protein phosphatase hVH2
-
-
-
-
Dual specificity protein phosphatase hVH3
-
-
-
-
Dual specificity protein phosphatase PYST1
-
-
-
-
Dual specificity protein phosphatase PYST2
-
-
-
-
Dual specificity protein phosphatase VHR
-
-
-
-
dual specifity protein phosphatase
-
-
dual-specificity (Thr/Tyr) MAPK protein phosphatase
-
-
dual-specificity phosphatase
-
-
dual-specificity protein phosphatase
-
-
dual-specificity protein tyrosine phosphatase 18
-
-
Dual-specificity tyrosine phosphatase TS-DSP6
-
-
-
-
Dual-specificity tyrosine phosphatase YVH1
-
-
-
-
ED-Eya2
O00167
-
ES cell phosphatase
-
-
-
-
FAP-1
-
-
Fap1
-
-
FLP1
-
-
GLEPP1
Q16827
-
HCP
-
-
-
-
HD-PTP
Q9H3S7
-
Hematopoietic cell protein-tyrosine phosphatase
-
-
-
-
Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP
-
-
-
-
hematopoietic protein tyrosine phosphatase
-
-
Hematopoietic protein-tyrosine phosphatase
-
-
-
-
hematopoietic tyrosine phosphatase
-
-
HEPTP
-
-
-
-
HEPTP
-
-
HEPTP
-
HePTP negatively regulates T cell activation and proliferation
HEPTP
P35236
-
histidine acid phosphatase
-
-
HPTP beta-like tyrosine phosphatase
-
-
-
-
HPTP eta
-
-
-
-
HPTPbeta
-
-
HPTPbeta-CD
-
-
hPTPE1
-
-
-
-
IA-2
Q16849
-
IA-2beta
Q92932
-
ICAAR
-
-
-
-
islet cell antigen-related PTP
-
-
Islet cell autoantigen related protein
-
-
-
-
KIM-containing PTP
-
-
KIM-PTP
-
-
kinase associated phosphatase
-
-
-
-
kinase interaction motif phosphatase
-
-
kinase interaction motif-containing protein tyrosine phosphatases
-
-
L-CA
-
-
-
-
LAR
-
member of the R2A subtype of receptor-like PTPs
LAR
P10586
-
Late protein H1
-
-
-
-
LCA
-
-
-
-
LCA-related phosphatase
-
-
-
-
leucocyte common antigen-related protein tyrosine phosphatase
-
-
Leukocyte antigen related
-
-
-
-
leukocyte common antigen-related
-
-
LmACR2
-
-
LMW-PTP
-
-
Low molecular weight cytosolic acid phosphatase
-
-
-
-
low molecular weight protein tyrosine phosphatase
-
-
low molecular weight protein tyrosine phosphatase
-
-
low molecular weight-PTP
-
-
low-molecular-weight protein tyrosine phosphatase
Q72JF6
-
LRP
-
-
-
-
Lymphoid phosphatase
-
-
-
-
lymphoid-specific tyrosine phosphatase
-
-
LyP
-
-
-
-
LyP
Q9Y2R2
-
M1851
-
-
-
-
MAP kinase phosphatase
Q16828, Q99956, Q9Y6W6
-
MAP-kinase phosphatase CPG21
-
-
-
-
MAPK-specific tyrosine phosphatase
P35236, P54829, Q15256
-
MEG
-
-
-
-
mitogen-activated protein kinase phosphatase
Q16828, Q99956, Q9Y6W6
-
mitogen-activated protein kinase phosphatase-1
-
-
mitogen-activated protein kinase-specific tyrosine phosphatase
P35236, P54829, Q15256
-
Mitosis initiation protein
-
-
-
-
Mitosis initiation protein MIH1
-
-
-
-
Mitotic inducer homolog
-
-
-
-
MKP-1
-
trivial names CL100, erp, 3CH134, hVH1
MKP-1 like protein tyrosine phosphatase
-
-
-
-
MKP-2
-
trivial names Typ1, Sty8, hVH2
MKP-3
-
trivial names Pyst1, rVH6
MKP-3
Q16828
-
MKP-4
-
trivial name Pyst3
MKP-4
Q99956
-
MKP-5
-
trivial names M3/6, hVH5, HB5
MKP-5
Q9Y6W6
-
MKP-7
-
-
MKP-X
-
trivial names Pyst2, B59
MKP1
-
a dual-specificity phosphatase
MPTP
-
-
-
-
MPTP-PEST
-
-
-
-
NC-PTPCOM1
-
-
-
-
Neural-specific protein-tyrosine phosphatase
-
-
-
-
non-receptor protein tyrosine phosphatase
-
-
ORF5
-
-
-
-
OST-PTP
-
-
-
-
OST-PTP
-
-
P19-PTP
-
-
-
-
p52shc
-
-
p65 PTPepsilon
-
-
p66shc
-
-
p67 PTPepsilon
-
-
P80
-
-
-
-
PC12-PTP1
-
-
-
-
Phogrin
-
-
-
-
Phosphacan
-
-
-
-
phosphatase of regenerating liver-3
-
-
phosphatase, phosphoprotein (phosphotyrosine)
-
-
-
-
phosphatase, phosphotyrosine
-
-
-
-
phosphoprotein phosphatase (phosphotyrosine)
-
-
-
-
phosphotyrosine histone phosphatase
-
-
-
-
phosphotyrosine phosphatase
-
-
-
-
Phosphotyrosine phosphatase 13
-
-
-
-
phosphotyrosine phosphatase 1B
-
-
phosphotyrosine protein phosphatase
-
-
-
-
phosphotyrosine-specific PP
-
-
phosphotyrosylprotein phosphatase
-
-
-
-
Pmp1p
Schizosaccharomyces pombe MI200
-
-
-
PP2A
-
-
PPM
-
the recombinant protein exhibits protein-tyrosine phosphatase in addition to its predicted protein-serine/threonine phosphatase activity
PPT-phosphatase
-
-
PRL-1
Q6JHV2
-
PRL-related protein tyrosine phosphatase
-
-
protein of regenerating liver-related protein tyrosine phosphatase
-
-
protein phosphatase 2A
-
-
protein phosphotyrosine phosphatase
-
-
-
-
protein Tyr phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
O14522, P10586, P17706, P18031, P18433, P23467, P23468, P23469, P23470, P23471, P26045, P28827, P29074, P29350
-
protein tyrosine phosphatase
P30304, P30305, P30307
-
protein tyrosine phosphatase
P35236, P43378, P54829, Q05209, Q06124, Q0VAE8, Q12913, Q12923, Q13332, Q15256, Q15262, Q15678, Q16825, Q16827, Q16849, Q4JDK3, Q92729, Q92932, Q99952, Q9H3S7, Q9HD43, Q9UMZ3, Q9Y2R2
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
Metarhizium anisopliae CQMa102
-
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
Mus musculus BALB/c
-
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
Trypanosoma cruzi Brener
-
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
Yersinia enterolytica
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase
-
-
protein tyrosine phosphatase 1B
-
-
protein tyrosine phosphatase 1B
-
-
protein tyrosine phosphatase 1B
-
-
protein tyrosine phosphatase A
-
-
protein tyrosine phosphatase alpha
-
-
protein tyrosine phosphatase B
-
-
protein tyrosine phosphatase beta
-
-
protein tyrosine phosphatase epsilon
-
-
protein tyrosine phosphatase eta
-
-
protein tyrosine phosphatase H1
-
-
protein tyrosine phosphatase ny
-
-
Protein tyrosine phosphatase receptor-type T
-
-
protein tyrosine phosphatase SHP-1
-
-
protein tyrosine phosphatase sigma
-
-
protein tyrosine phosphatase xi
-
-
protein tyrosine phosphatase, receptor-type, Z polypeptide 1
-
-
protein tyrosine phosphatase-1B
-
-
protein tyrosine phosphatase-1B
-
-
protein tyrosine phosphatase-1B
-
-
protein tyrosine phosphatase-2
-
-
protein tyrosine phosphatase-BL
-
-
protein tyrosine phosphatase-H2
-
-
Protein tyrosine phosphatase-NP
-
-
-
-
Protein-protein-tyrosine phosphatase HA2
-
-
-
-
protein-tyrosine phosphatase
-
-
protein-tyrosine phosphatase
Q0PEE2
-
protein-tyrosine phosphatase
Leishmania donovani 1S/Cl2D
Q0PEE2
-
-
protein-tyrosine phosphatase
-
-
protein-tyrosine phosphatase
Leishmania major Friedlin V9
-
-
-
Protein-tyrosine phosphatase 1B
-
-
-
-
Protein-tyrosine phosphatase 1C
-
-
-
-
Protein-tyrosine phosphatase 1E
-
-
-
-
Protein-tyrosine phosphatase 2C
-
-
-
-
Protein-tyrosine phosphatase 2E
-
-
-
-
Protein-tyrosine phosphatase 3CH134
-
-
-
-
protein-tyrosine phosphatase alpha
-
-
Protein-tyrosine phosphatase CL100
-
-
-
-
Protein-tyrosine phosphatase D1
-
-
-
-
Protein-tyrosine phosphatase D1
-
-
Protein-tyrosine phosphatase ERP
-
-
-
-
Protein-tyrosine phosphatase G1
-
-
-
-
Protein-tyrosine phosphatase H1
-
-
-
-
Protein-tyrosine phosphatase LC-PTP
-
-
-
-
Protein-tyrosine phosphatase MEG1
-
-
-
-
Protein-tyrosine phosphatase MEG2
-
-
-
-
Protein-tyrosine phosphatase P19
-
-
-
-
Protein-tyrosine phosphatase PCPTP1
-
-
-
-
Protein-tyrosine phosphatase pez
-
-
-
-
Protein-tyrosine phosphatase PTP-RL10
-
-
-
-
Protein-tyrosine phosphatase PTP36
-
-
-
-
Protein-tyrosine phosphatase PTPL1
-
-
-
-
Protein-tyrosine phosphatase striatum-enriched
-
-
-
-
Protein-tyrosine phosphatase SYP
-
-
-
-
Protein-tyrosine-phosphatase SL
-
-
-
-
Protein-tyrosine-phosphate phosphohydrolase
-
-
-
-
PTEN
-
-
PTEN phosphoprotein phosphatase
-
-
PTP
O14522, P10586, P17706, P18031, P18433, P23467, P23468, P23469, P23470, P23471, P26045, P28827, P29074, P29350
-
PTP
P30304, P30305, P30307
-
PTP
P35236, P43378, P54829, Q05209, Q06124, Q0VAE8, Q12913, Q12923, Q13332, Q15256, Q15262, Q15678, Q16825, Q16827, Q16849, Q4JDK3, Q92729, Q92932, Q99952, Q9H3S7, Q9HD43, Q9UMZ3, Q9Y2R2
-
PTP 1B
-
-
PTP epsilon
-
-
PTP IA-2beta
-
-
-
-
PTP-1B
-
-
-
-
PTP-1B
-
-
PTP-1C
-
-
-
-
PTP-1D
-
-
-
-
PTP-2C
-
-
-
-
PTP-BAS
-
-
-
-
PTP-BAS
-
-
PTP-BL
-
-
PTP-E1
-
-
-
-
PTP-eta
-
-
PTP-H1
-
-
-
-
PTP-HA2
-
-
-
-
PTP-MEG2
-
-
PTP-MEG2
-
-
PTP-NP
-
-
-
-
PTP-oc
-
the protein is produced from the distal promotor, PTP-oc is identical to PTPRO, except that its extracellular domain is extremely short with eight amino acids in all
PTP-PEST
-
-
PTP-PEST
Q05209
-
PTP-PEST
-
-
PTP-PEST
-
a non-receptor protein tyrosine phosphatase
PTP-phosphatase
-
-
PTP-SH2beta
-
-
-
-
PTP-SL
-
receptor-type isoform
PTP1
-
-
PTP1
Q0PEE2
-
PTP1
Leishmania donovani 1S/Cl2D
Q0PEE2
-
-
PTP1
Leishmania major Friedlin V9
-
-
-
PTP1B
P18031
-
PTP1C
-
-
-
-
PTP1D
-
-
-
-
PTP1e
-
-
PTP2C
-
-
-
-
PTP36
Q15678
-
PTP36
-
-
PTPalpha
-
-
PTPalpha
-
-
PTPalpha
-
a receptor-type protein-tyrosine phosphatase
PTPase
Metarhizium anisopliae CQMa102
-
-
-
PTPase
Q72JF6
-
PTPase YVH1
-
-
-
-
PTPase-MEG1
-
-
-
-
PTPase-MEG1
P29074, Q06124
-
PTPase-MEG2
-
-
-
-
PTPase-MEG2
P43378
-
PTPB1
-
-
PTPBAS
Q12923
-
PTPBR7
-
membrane isoform
PTPBR7
-
receptor-type isoform
PTPD1
-
PTPD1 is a cytosolic nonreceptor tyrosine phosphatase and a positive regulator of the Src-epidermal growth factor transduction pathway
PTPD1
Q16825
-
PTPepsilon
-
-
PTPepsilon
-
belongs to the receptor-type branch of the PTP family
PTPepsilonC
-
non-receptor-type isoform of PTPepsilon
PTPepsilonM
-
receptor-type isoform of PTPepsilon
PTPetaCD
-
catalytic domain of protein tyrosine phosphatase eta
PTPG1
-
-
-
-
PTPgamma
-
-
PTPH1
P26045
-
PTPH1
-
-
PTPL1
-
-
PTPMEG
-
-
PTPN1
-
-
PTPN11
-
-
PTPN11
Q06124
-
PTPN11
-
-
PTPN12
Q05209
-
PTPN12
-
-
PTPN13
Q12923
-
PTPN14
Q15678, Q99952
-
PTPN2
-
-
PTPN20 variant 15
Q4JDK3
-
PTPN21
Q16825
-
PTPN22
-
-
PTPN22
Q9Y2R2
-
PTPN23
Q9H3S7
-
PTPN3
-
a non-receptor protein tyrosine phosphatase
PTPN4
P29074
-
PTPN4
-
-
PTPN4
-
a non-receptor protein tyrosine phosphatase
PTPN4/PTP-MEG1
-
a PTPH1-family member
PTPN5
-
-
PTPN5
P54829
-
PTPN5
P54829
also called striatal-enriched phosphatase or STEP
PTPN5
-
-
PTPN6
-
-
-
-
PTPN6
P29350
-
PTPN6
-
-
PTPN7
-
-
PTPN7
P35236
-
PTPN7
P35236
also called hematopoietic PTP
PTPN7
-
-
PTPN9
P43378
-
PTPN9
-
-
PTPNE6
-
-
-
-
PTPP
-
-
PTPPase
-
-
PTPPBSgamma
-
cytosolic isoform
PTPPBSgamma-37
-
cytosolic isoform
PTPPBSgamma-42
-
cytosolic isoform
PTPRA
P18433
-
PTPRB
P23467
-
PTPRC
Q0VAE8
-
PTPRD
P23468
-
PTPRE
P23469
-
PTPRF
P10586
-
PTPRG
P23470
-
PTPRH
Q9HD43
-
PTPRJ
Q12913
-
PTPRK
Q15262
-
PTPRM
P28827
-
PTPRN
Q16849
-
PTPRN2
Q92932
-
PTPRO
Q16827
-
PTPRO
-
a receptor-type PTP, the protein is produced from the distal promotor
PTPRO, truncated
-
the protein is produced from the proximal promotor
PTPROt
-
the protein is produced from the proximal promotor
PTPRQ
Q9UMZ3
-
PTPRR
-
-
PTPRR
Q15256
-
PTPRR
Q15256
also called PC12 PTP or STEP-like PTP
PTPRR
-
-
PTPRS
Q13332
-
PTPRT
O14522
-
PTPRU
Q92729
-
PTPRV
-
-
PTPRZ
P23471
-
PTPRZ1
-
-
PTPS31
Q9UMZ3
-
PTPsigma
-
-
PTPxi/RPTPbeta
-
-
PY protein phosphatase
-
-
-
-
Pyp1p
Schizosaccharomyces pombe MI200
-
-
-
Pyp2p
Schizosaccharomyces pombe MI200
-
-
-
R-PTP-alpha
-
-
-
-
R-PTP-beta
-
-
-
-
R-PTP-delta
-
-
-
-
R-PTP-epsilon
-
-
-
-
R-PTP-eta
-
-
-
-
R-PTP-gamma
-
-
-
-
R-PTP-kappa
-
-
-
-
R-PTP-mu
-
-
-
-
R-PTP-zeta
-
-
-
-
R2B phosphatase
-
-
R2B phosphatase
Mus musculus C57BL/6J
-
-
-
receptor protein tyrosine phosphatase
-
-
receptor protein tyrosine phosphatase rho
-
-
receptor protein tyrosine phosphatase rho
Mus musculus C57BL/6J
-
-
-
receptor protein tyrosine phosphatase T
-
-
receptor protein tyrosine phosphatase {kappa}
-
-
Receptor-linked protein-tyrosine phosphatase 10D
-
-
-
-
Receptor-linked protein-tyrosine phosphatase 99A
-
-
-
-
receptor-type protein tyrosine phosphatase J
-
-
Receptor-type protein-tyrosine phosphatase-kappa
-
-
RNA/RNP complex-intereracting phosphatase
-
-
-
-
ROL B protein
-
-
-
-
RPTPalpha
-
-
-
-
RPTPalpha
-
-
RPTPalpha
P18433
-
RPTPdelta
P23468
-
RPTPepsilon
P23469
-
RPTPepsilon
-
receptor-type isoform of PTPepsilon
RPTPgamma
P23470
-
RPTPkappa
-
-
RPTPkappa
Q15262
-
RPTPlambda
Q92729
-
RPTPmu
P28827
-
RPTPrho
O14522
-
RPTPrho/PTPRT
-
-
RPTPrho/PTPRT
Mus musculus C57BL/6J
-
-
-
RPTPsigma
Q13332
-
RPTPzeta
P23471
-
Saci-PTP
Q4JB88
dual specific phosphatase EC 3.1.3.16/EC 3.1.3.48
Saci-PTP
Sulfolobus acidocaldarius MW001
Q4JB88
dual specific phosphatase EC 3.1.3.16/EC 3.1.3.48
-
Saci0545
Q4JB88
locus name, dual specific phosphatase EC 3.1.3.16/EC 3.1.3.48
Saci0545
Sulfolobus acidocaldarius MW001
Q4JB88
locus name, dual specific phosphatase EC 3.1.3.16/EC 3.1.3.48
-
SAP1
Q9HD43
-
Scr homology 2-containing tyrosine phosphatase
-
-
SH-PTP1
-
-
-
-
SH-PTP2
-
-
-
-
SH-PTP3
-
-
-
-
SH2 domain-containing tyrosine phosphatase-1
-
-
SH2 domain-containing tyrosine phosphatase-2
-
-
SHP
-
-
-
-
SHP-1
-
also known as PTP1C and SH-PTP1
SHP-1
-
SHP-1 is a nontransmembrane PTP
SHP-1
Mus musculus BALB/c
-
-
-
SHP-1
-
also known as PTP1C and SH-PTP1
SHP-2
-
also known as PTP1D and SH-PTP2
SHP-2
-
-
SHP-2
-
also known as PTP1D and SH-PTP2
SHP1
P29350
-
SHP2
-
Shp2 is a nonreceptor PTP that plays a positive role in cell signaling by growth factors and cytokines and is involved in regulation of cell proliferation, differentiation, and migration
Small tyrosine phosphatase
-
-
-
-
Small, acidic phosphotyrosine protein phosphatase
-
-
-
-
SPH-1
-
-
SPH-2
-
-
Src homology 2 domain-containing phosphatase-1
-
-
Src homology region 2 domain-containing phosphatase 1
-
-
Src homology-2 domain containing protein tyrosine phosphatase-1
-
-
Src homology-2 domain containing protein tyrosine phosphatase-2
-
-
STEP
-
-
-
-
STEP
-
-
STEP
P54829
-
STEP
-
-
STEP33
-
STEP is processed into a 33 kDa isoform by calpain-mediated cleavage, STEP33 retains catalytic activity but is unable to bind to phosphorylated ERK
STEP46
-
recombinant enzyme
STEP61
-
STEP61 is the normally expressed enzyme form
striatal enriched protein tyrosine phosphatase
-
-
striatal-enriched PTP
-
-
striatal-enriched PTP
-
-
String protein
-
-
-
-
Syp
-
-
-
-
T cell protein tyrosine phosphatase
-
-
T-cell protein tyrosine phosphatase
-
-
T-cell protein tyrosine phosphatase
-
-
T-cell protein tyrosine phosphatase
-
-
T-cell protein-tyrosine phosphatase
-
-
-
-
T-cell PTP
-
-
T-DSP11
-
-
-
-
T200
-
-
-
-
TC PTP
-
-
TC-PTPase
-
-
TCPTP
-
-
-
-
TCPTP
P17706
-
TCPTP/TC45
-
-
TcPTP1
Trypanosoma cruzi Brener
-
-
-
testis- and skeletal-muscle-specific DSP
-
-
testis- and skeletal-muscle-specific dual specificity protein phosphatase
-
-
Testis-and skeletal-muscle-specific DSP
-
-
-
-
TMDP
-
-
TypPT
Q4JDK3
-
tyrosine O-phosphate phosphatase
-
-
-
-
tyrosine phosphatase
-
-
tyrosine phosphatase alpha
-
-
Tyrosine phosphatase CBPTP
-
-
-
-
tyrosine phosphatase epsilon
-
-
tyrosine phosphatase Src homology region 2 domain-containing phosphatase 1
-
-
tyrosine phosphatase Src homology region 2 domain-containing phosphatase 1
Mus musculus BALB/c
-
-
-
tyrosine-specific MAPK phosphatase
-
-
tyrosylprotein phosphatase
-
-
-
-
vaccinia H1-related PTP
Q16828, Q99956, Q9Y6W6
-
VE-PTP
P23467
-
VHR
P30304, P30305, P30307
-
VHR
Q16828, Q99956, Q9Y6W6
-
YopH
-
-
YopH
Yersinia enterolytica
-
-
[phosphotyrosine]protein phosphatase
-
-
-
-
MKP5-C
Q16828, Q99956, Q9Y6W6
catalytic domain of MKP5
additional information
-
CRYP-2 is identical in sequence to the human glomerular epithelial protein-1
additional information
-
SHP-1 belongs to the family of non-receptor protein tyrosine phosphatases
additional information
-
the enzyme belongs to the LMW-PTP family
additional information
O00167
ED-Eya2 belongs to the haloacid dehalogenase family
additional information
-
SHP-1 is a member of SH2 domain-containing PTP subfamily
additional information
-
the enzyme is a member of the PTP family
CAS REGISTRY NUMBER
COMMENTARY
79747-53-8
-
97162-86-2
-
ORGANISM
COMMENTARY
LITERATURE
SEQUENCE CODE
SEQUENCE DB
SOURCE
enzymes Y-1, Y-2 and Y-3
-
-
Manually annotated by BRENDA team
isoform low molecular mass protein tyrosine phosphatase
-
-
Manually annotated by BRENDA team
i.e. CvBV, gene CvBV202. Cotesia vestalis is a solitary endoparasitoid wasp of the larval stage of the diamondback moth, Plutella xylostella, and injects a polydnavirus, CvBV, into its host during oviposition
-
-
Manually annotated by BRENDA team
subspecies Francisella tularensis holarctica
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
Cdc25B
SwissProt
Manually annotated by BRENDA team
Cdc25C
SwissProt
Manually annotated by BRENDA team
classification of subfamilies, overview
-
-
Manually annotated by BRENDA team
comercial preparation
-
-
Manually annotated by BRENDA team
epsilon isoform
SwissProt
Manually annotated by BRENDA team
GenBank, EMBL Data Bank L07527
UniProt
Manually annotated by BRENDA team
gene PTPN22
-
-
Manually annotated by BRENDA team
isoform CD45
-
-
Manually annotated by BRENDA team
isoform PTP-1B and TCPTP
-
-
Manually annotated by BRENDA team
isoform PTP1B
SwissProt
Manually annotated by BRENDA team
isoform PTP1B
-
-
Manually annotated by BRENDA team
isoform PTP1B, amino acids 1-400, catalytic domain plus 80-amino acid C-terminal tail
SwissProt
Manually annotated by BRENDA team
isoform PTP1B, recombinant enzyme
-
-
Manually annotated by BRENDA team
isoform PTPN22, expressed exclusively in cells of hematopoietic origin
-
-
Manually annotated by BRENDA team
isoform Receptor-type protein-tyrosine phosphatase-kappa
-
-
Manually annotated by BRENDA team
isoforms PTP1B and PTPbeta
SwissProt
Manually annotated by BRENDA team
isoforms PTP1B, CD45, comercial preparations
-
-
Manually annotated by BRENDA team
isoforms PTP1B, CD45, PTPalpha, LAR
-
-
Manually annotated by BRENDA team
isoforms PTPB1, PTPH1
SwissProt
Manually annotated by BRENDA team
isozyme PTP1B
-
-
Manually annotated by BRENDA team
isozyme SHP-1
UniProt
Manually annotated by BRENDA team
isozymes PTP1B, PTPalpha
-
-
Manually annotated by BRENDA team
MKP-3
SwissProt
Manually annotated by BRENDA team
MKP-4
SwissProt
Manually annotated by BRENDA team
MKP-5
SwissProt
Manually annotated by BRENDA team
phosphatase subtype 1A and 1B
-
-
Manually annotated by BRENDA team
protein isoform PTP1B
-
-
Manually annotated by BRENDA team
PTPN5
SwissProt
Manually annotated by BRENDA team
PTPN7
SwissProt
Manually annotated by BRENDA team
PTPRR
SwissProt
Manually annotated by BRENDA team
receptor-type protein tyrosine phosphatase CD148
-
-
Manually annotated by BRENDA team
recombinant enzyme
-
-
Manually annotated by BRENDA team
recombinant enzyme PTP1B
SwissProt
Manually annotated by BRENDA team
recombinant enzyme, expression in Escherichia coli and L cell
-
-
Manually annotated by BRENDA team
recombinant protein expressed in various human cell lines
-
-
Manually annotated by BRENDA team
transgenic expression in mice muscle
-
-
Manually annotated by BRENDA team
two isozymes
-
-
Manually annotated by BRENDA team
two isozymes of LMW-PTP, and PTP-1B
Uniprot
Manually annotated by BRENDA team
strain 1S/Cl2D
EMBL
Manually annotated by BRENDA team
Leishmania donovani 1S/Cl2D
strain 1S/Cl2D
EMBL
Manually annotated by BRENDA team
strain Friedlin V9
-
-
Manually annotated by BRENDA team
Leishmania major Friedlin V9
strain Friedlin V9
-
-
Manually annotated by BRENDA team
bifunctional antimonate reductase/protein tyrosine phosphatase
-
-
Manually annotated by BRENDA team
low molecular weight enzyme subfamily, overview
-
-
Manually annotated by BRENDA team
transmembrane and cytosolic isozymes
-
-
Manually annotated by BRENDA team
strain CQMa102
-
-
Manually annotated by BRENDA team
Metarhizium anisopliae CQMa102
strain CQMa102
-
-
Manually annotated by BRENDA team
C57BL/6J mice and male ob/ob mice
-
-
Manually annotated by BRENDA team
female wild-type C57BL/6 mice
-
-
Manually annotated by BRENDA team
GenBank accession numbers are PTP36-A: AF170902, PTP36-B: AF170903, PTP36-C: AF170904
-
-
Manually annotated by BRENDA team
GenBank accession numbers are PTP36-A: AF170902, PTP36-B: AF170903, PTP36-C: AF170904; GenBank D64141
-
-
Manually annotated by BRENDA team
GenBank accession numbers are PTP36-A: AF170902, PTP36-B: AF170903, PTP36-C: AF170904; PTP36-D: Af170905, tissue-dependent expressions of isoforms
Uniprot
Manually annotated by BRENDA team
homozygous PTP1B-deficient animal, hyperresponsive to insulin and leptin and resistant to diet-induced obesity
-
-
Manually annotated by BRENDA team
isoform protein tyrosine phosphatase alpha, enzyme-deficinet animal
-
-
Manually annotated by BRENDA team
isozyme TC45
-
-
Manually annotated by BRENDA team
strain C57BL/6J
-
-
Manually annotated by BRENDA team
two LMW-PTP isozymes
-
-
Manually annotated by BRENDA team
Mus musculus BALB/c
-
-
-
Manually annotated by BRENDA team
Mus musculus C57BL/6J
strain C57BL/6J
-
-
Manually annotated by BRENDA team
isozymes MPtpA, MPtpB
-
-
Manually annotated by BRENDA team
strain 3D7
-
-
Manually annotated by BRENDA team
adult female Sprague Dawley rats
-
-
Manually annotated by BRENDA team
alternative splicing produces 3 isoforms: PTPxi-A, the full-length form, PTPxi-B, the short form and PTPxi-S an extracellular variant
-
-
Manually annotated by BRENDA team
enzymes PTP-I, PTP-II, PTP-III
-
-
Manually annotated by BRENDA team
isoform Shp2
-
-
Manually annotated by BRENDA team
isozyme OST-PTP
-
-
Manually annotated by BRENDA team
male Wistar rats
-
-
Manually annotated by BRENDA team
Schizosaccharomyces pombe MI200
strain MI200
-
-
Manually annotated by BRENDA team
psychrophilic microorganism, recombinant enzyme
-
-
Manually annotated by BRENDA team
LMW-PTP, isozymes PtpA and PtpB
-
-
Manually annotated by BRENDA team
two low-molecular-weight protein tyrosine phosphatases, PtpA and PtpB
-
-
Manually annotated by BRENDA team
A3(2), GenBank U37580
-
-
Manually annotated by BRENDA team
the wild type strain DSM 639 missing 322 bp called MW001
UniProt
Manually annotated by BRENDA team
Sulfolobus acidocaldarius MW001
the wild type strain DSM 639 missing 322 bp called MW001
UniProt
Manually annotated by BRENDA team
ORF slr0328
-
-
Manually annotated by BRENDA team
strain PCC 6803, isoforms SynPPP1 and SynPPM3 both acting on phosphotyrosine- as well as phosphoserine-containing proteins
-
-
Manually annotated by BRENDA team
strain HB27
UniProt
Manually annotated by BRENDA team
isoform PRL-1
SwissProt
Manually annotated by BRENDA team
Trypanosoma cruzi Brener
-
-
-
Manually annotated by BRENDA team
encoded on a virulence plasmid
Uniprot
Manually annotated by BRENDA team
Yersinia enterolytica
-
-
-
Manually annotated by BRENDA team
isoform YOP
-
-
Manually annotated by BRENDA team
isoform YOP, comercial preparation
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
evolution
-
Protein tyrosine phosphatases form a large family of enzymes involved in the regulation of numerous cellular functions in eukaryotes
evolution
Trypanosoma cruzi Brener
-
Protein tyrosine phosphatases form a large family of enzymes involved in the regulation of numerous cellular functions in eukaryotes
-
malfunction
-
the enzyme is involved in the negative regulation of several cancer relevant cellular signalling pathways
malfunction
-
PTPB1 is involved in type II diabetes
malfunction
-
bone marrow-derived macrophages lacking significant SHP-1 activity display a profound defect in interleukin-12p40 synthesis in response to lipopolysaccharide, peptidoglycan, and synthetic Toll-like receptor ligands, while producing normal amounts of other proinflammatory cytokines, such as TNFalpha and interleukin-6
malfunction
-
protein tyrosine phosphatases inactivate neurotrophic factor receptors and downstream intracellular signaling molecules causing neurodegeneration and loss of sensoric functions, overview
malfunction
-
CRYP-2 is involved in hepatic carcinomas, inhibition of CRYP-2 is of tremendous therapeutic importance
malfunction
-
neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMP-activated protein kinase, AMPK, and isoform-specific activation of AMPK in peripheral tissues, overview
malfunction
-
PTPs are integral components of key cell survival pathways, and are responsible for their inactivation, while PTP inhibition is are often associated with enhanced cell proliferation, overview. PTP inhibition in the presence of certain types of DNA damage may lead to increased genomic instability, via bypass of cell cycle checkpoints
malfunction
-
PTPRZ1 is implicated in glioblastoma pathogenesis
malfunction
-
the Cowden syndrome-associated G129E mutation abrogates the phospholipid phosphatase activity but not the phosphoprotein phosphatase activity of PTEN
malfunction
-
improperly regulated PTP activity has been implicated in a range of human diseases including leukemia, solid-tumor cancers, diabetes, and several autoimmune disorders
malfunction
-
loss of SHP-1 expression strongly augments the ability of regulatory T cells to suppress inflammation in a mouse model. Specific pharmacological inhibition of SHP-1 enzymatic activity via the cancer drug sodium stibogluconate potently augmented regulatory T cell suppressor activity both in vivo and ex vivo. SHP-1-deficient regulatory T cells are more efficient suppressors T-cell activation than wild-type regulatory T-cells
malfunction
Mus musculus BALB/c
-
loss of SHP-1 expression strongly augments the ability of regulatory T cells to suppress inflammation in a mouse model. Specific pharmacological inhibition of SHP-1 enzymatic activity via the cancer drug sodium stibogluconate potently augmented regulatory T cell suppressor activity both in vivo and ex vivo. SHP-1-deficient regulatory T cells are more efficient suppressors T-cell activation than wild-type regulatory T-cells
-
physiological function
Q72JF6
the heat-resistant PTPase may play important roles in vivo in the adaptation of the microorganism to extreme temperatures and specific nutritional conditions
physiological function
-
MptpA and MptpB selectively dephosphorylate human host proteins involved in interferon-gamma signaling pathways, thereby preventing the initiation of host defense mechanisms, overview
physiological function
P24666
protein tyrosine phosphatases are crucial elements in eukaryotic signal transduction
physiological function
-
SHP-1 is important in the negative regulation of JAK/STAT signaling and is often silenced by methylation in leukemias and lymphomas
physiological function
-
PTPH1 might play a role in the positive regulation of the LPS-induced cytokines release in vivo, in contrast to previous reports indicating PTPH1 as potential negative regulator of immune response
physiological function
-
SHP-1 plays critical roles in regulation of many receptor-mediated signaling cascades in the immune system, and it represents a mechanism for host regulation of a specific proinflammatory cytokine important in both innate and adaptive immunity. It is required for SHP-1 in interleukin-12/23 p40 production in response to Toll-like receptor stimulation in macrophages. SHP-1 regulation of interleukin-12p40 transcription requires both its catalytic activity and phosphotyrosine binding by its N-terminal SH2 domain and is mediated via repression of, and interaction with, phosphatidylinositol 3-kinase, without affecting c-Rel activation, overview
physiological function
-
isozyme p52shc plays an essential role in mediating IGF-I activation of MAP kinases in smooth muscle cells, involving also protein tyrosine phosphatase-2, while isozyme p66shc inhibits IGF-I signal transduction, overview. p66shc functions to negatively regulate the formation of a signaling complex that is required for p52shc activation in response to IGF-I, thus leading to attenuation of IGF-I-stimulated cell proliferation and migration
physiological function
-
PTPs are integral components of key cell survival pathways, and are responsible for their inactivation, while PTP inhibition is are often associated with enhanced cell proliferation, overview
physiological function
-
SHP-1 is involved in the PI3K-AKT pathway interacting with PI3K and regulating its activity and p110 catalytic subunit phosphorylation
physiological function
-
PTPRT is involved in important signaling pathway that plays a critical role in colorectal tumorigenesis, overview
physiological function
-
protein tyrosine phosphatases are a large and important class of signaling enzymes that catalyze the dephosphorylation of phosphotyrosine in protein substrates. A number of PTPs are tumor-suppressor proteins. PEST is a wide-ranging and ubiquitously expressed signaling molecule, which is involved in the regulation of osteoclast activation, cell motility and adhesion, the immune response, and apoptosis
physiological function
-
PTP1B-mediated dephosphorylation of Gab1 negatively affects its EGF-induced association with the phosphatase SHP2. The dissociation of this signaling complex is accompanied by a decrease of ERK MAP kinase phosphorylation and activation. PTP1B specifically interferes with SHP2 recruitment by Gab1 and with ERK1/2 activation
physiological function
-
SHP-1 generally acts as a negative regulator in a variety of cellular signaling pathways
physiological function
-
the cytoplasmic tyrosine phosphatase Src homology region 2 domain-containing phosphatase 1, SHP-1, acts as an endogenous brake and modifier of the suppressive ability of regulatory T cells, which are important for immune tolerance. Regulatory T cells prevent the activation of conventional T cells. Regulatory T cell -mediated suppression of Tcon activation occurs by multiple mechanisms and is regulated by SHP-1, overview
physiological function
-
PtpA is not essential for in vitro growth
physiological function
Mus musculus BALB/c
-
the cytoplasmic tyrosine phosphatase Src homology region 2 domain-containing phosphatase 1, SHP-1, acts as an endogenous brake and modifier of the suppressive ability of regulatory T cells, which are important for immune tolerance. Regulatory T cells prevent the activation of conventional T cells. Regulatory T cell -mediated suppression of Tcon activation occurs by multiple mechanisms and is regulated by SHP-1, overview
-
metabolism
-
MPtpA is a signalling protein belonging to the tyrosine phosphatase superfamily, and is involved in phagocytosis and is active in virulent mycobacterial form
additional information
-
small-molecule protein tyrosine phosphatase inhibition is a neuroprotective treatment after spinal cord injury in adult rats
additional information
-
CRC cells homozygous for a paxillin Y88F knock-in mutant exhibit significantly reduced cell migration and impaired anchorage-independent growth, and they fail to form xenograft tumors in nude mice, and have decreased phosphorylation of p130CAS, SHP2, and AKT
additional information
-
PTP-H2 expression is restricted to hemocytes in Microplitis demolitor bracovirus -infected hosts
additional information
-
GST pull-down experiment with pervanadate-treated, to increase and preserve tyrosine phosphorylation, RAW264.7 cell lysates with either GST alone, wild-type Lyp fused to GST (GST-Lyp), or the substrate-trapping fusion proteins GST-Lyp/C227S and GST-Lyp/D195A. Whereas no protein retained by GST or GST-Lyp is detectable, the GST-Lyp/C227S and GST-Lyp/D195A trapping mutants specifically bound SKAP-HOM, the failure to detect association of SKAP-HOM with wild-type Lyp indicates that the interaction between the Lyp trapping mutants and SKAP-HOM requires tyrosine phosphorylation
additional information
-
phosphatases interact only transiently with their substrates
additional information
-
the crystal structures of the tail-truncated SHP-1 and SHP-2 reveal an autoinhibitory conformation, regulatory mechanism, overview. Interactions between two SH2 domains and between the N-SH2 and the catalytic domains can be responsible for the stabilization of SHP-1 in the open, active conformation
additional information
-
Asp120 has an essentiality function as the general acid. Two adjacent tyrosine residues, Tyr122 and Tyr123, contribute to the deepening of the active-site pocket. Genetic deletion of ptpA or ptpB does not affect in vitro growth or cell wall integrity
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1-naphthyl phosphate + H2O
1-naphthol + phosphate
show the reaction diagram
-
-
-
-
?
1-naphthyl phosphate + H2O
1-naphthol + phosphate
show the reaction diagram
-
89.3% of the activity with 4-nitrophenyl phosphate, lung enzyme
-
-
?
3,6-fluorescein diphosphate + H2O
? + phosphate
show the reaction diagram
P18031
-
-
-
?
3-nitrobenzyl phosphate + H2O
3-nitrobenzyl alcohol + phosphate
show the reaction diagram
-
-
-
-
?
3-O-methylfluorescein phosphate + H2O
3-O-methylfluorescein + phosphate
show the reaction diagram
-
-
-
-
?
4-methylumbelliferyl phosphate + H2O
4-methylumbelliferone + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
Q06124
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
P18031
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
P35236
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
P24666
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
Q64604
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
P40347
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
P15273
-
-
-
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
Q6JHV2, -
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
Q9S427
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
Q72JF6
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
Trypanosoma cruzi Brener
-
-
-
-
?
4-nitrophenyl phosphate + H2O
nitrophenol + phosphate
show the reaction diagram
Q4JB88, -
-
-
-
?
4-nitrophenyl phosphate + H2O
nitrophenol + phosphate
show the reaction diagram
Sulfolobus acidocaldarius MW001
Q4JB88
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + H2O
show the reaction diagram
P18031
-
-
-
?
4-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenyl + phosphate
show the reaction diagram
-
-
-
-
?
4-nitrophenylphosphate + H2O
4-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferone + phosphate
show the reaction diagram
-
-
-
-
?
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferone + phosphate
show the reaction diagram
-
-
-
-
?
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferone + phosphate
show the reaction diagram
-
-
-
-
?
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferone + phosphate
show the reaction diagram
Q16828, Q99956, Q9Y6W6
-
-
-
?
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferol + phosphate
show the reaction diagram
-
-
-
-
?
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferol + phosphate
show the reaction diagram
-
-
-
-
?
AAAAApYEEVH + H2O
AAAAAYEEVH + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
AAAAApYRHRR + H2O
AAAAAYRHRR + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
Ac-AAAApYAAAA-NH2 + H2O
Ac-AAAAYAAAA-NH2 + phosphate
show the reaction diagram
-
-
-
-
?
Ac-AAAEpYAAAA-NH2 + H2O
Ac-AAAEYAAAA-NH2 + phoosphate
show the reaction diagram
-
-
-
-
?
Ac-AAAQpYAAAA-NH2 + H2O
Ac-AAAQYAAAA-NH2 + phosphate
show the reaction diagram
-
-
-
-
?
Ac-DGEEpYDDPF-NH2 + H2O
Ac-DGEEYDDPF-NH2 + phosphate
show the reaction diagram
-
SKAP-HOM Tyr75 peptide
-
-
?
Ac-ENDEpYTARE-NH2 + H2O
Ac-ENDEYTARE-NH2 + phosphate
show the reaction diagram
-
Lck Tyr394 peptide
-
-
?
Ac-TEPQpYQPGE-NH2 + H2O
Ac-TEPQYQPGE-NH2 + phosphate
show the reaction diagram
-
Lck Tyr505 peptide
-
-
?
Ac-YGEEpYDDLY-NH2 + H2O
Ac-YGEEYDDLY-NH2 + phosphate
show the reaction diagram
-
consensus peptide 1
-
-
?
Ac-YGYEpYDDEY-NH2 + H2O
Ac-YGYEYDDEY-NH2 + phosphate
show the reaction diagram
-
consensus peptide 2
-
-
?
acetyl-DADEpY-NH2 + H2O
acetyl-DADEY-NH2 + phosphate
show the reaction diagram
-
-
-
?
acetyl-DADEpYL-NH2 + H2O
acetyl-DADEYL-NH2 + phosphate
show the reaction diagram
P18031
-
-
?
ADEDFpYAA + H2O
ADEDFYAA + phosphate
show the reaction diagram
-
substrate of SHP-2
-
-
?
AKFEDTpYAA + H2O
AKFEDTYAA + phosphate
show the reaction diagram
-
substrate of SHP-1
-
-
?
angiotensin I + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
ApYR + H2O
AYR + phosphate
show the reaction diagram
-
-
-
-
?
ARKRIpYAA + H2O
ARKRIYAA + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
ASSDDpYAA + H2O
ASSDDYAA + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
ATP + H2O
ADP + phosphate
show the reaction diagram
Metarhizium anisopliae, Metarhizium anisopliae CQMa102
-
9.5% activity compared to TRDIpYETDYYRK
-
-
?
AVWEFpYpYAA + H2O
? + phosphate
show the reaction diagram
-
substrate of SHP-1
-
-
?
AWSpYADpYAA + H2O
? + phosphate
show the reaction diagram
-
substrate of SHP-1
-
-
?
AYTEpYTpYAA + H2O
? + phosphate
show the reaction diagram
-
substrate of SHP-1
-
-
?
beta-naphthyl phosphate + H2O
beta-naphthol + phosphate
show the reaction diagram
-
-
-
-
?
bis-(p-phosphophenyl) methane + H2O
?
show the reaction diagram
P18031
synthetic high-affinity low-molecular weight nonpeptide substrate
-
-
?
bovine serum albumin + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
bovine serum albumin + H2O
? + phosphate
show the reaction diagram
-
reduced, carboxamide methylated and succinylated
-
-
?
carboxyamidomethylated and maleylated lysozyme + H2O
?
show the reaction diagram
-
-
-
-
?
carrier protein-Cdc2-phosphotyrosine + H2O
carrier protein-Cdc2-tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
carrier protein-Y3-phosphotyrosine + H2O
carrier protein-Y3-tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
carrier protein-Y5-phosphotyrosine + H2O
carrier protein-Y5-tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
casein + H2O
?
show the reaction diagram
-
-
-
-
?
casein tyrosine phosphate + H2O
casein tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
Cdk2-pTpY + H2O
Cdk2-TpY + phosphate
show the reaction diagram
-
dephosphorylates Cdk/cyclins on pThr14 and/or pTyr15 residues
-
-
?
Cdk2-pTpY/CycA + H2O
Cdk2-pTY/CycA + phosphate
show the reaction diagram
-
-
-
-
?
DADEpYIPQQG + H2O
DADEYIPQQG + phosphate
show the reaction diagram
-
specific substrate for PTP1B
-
-
?
DADEpYLIPQQG + H2O
DADEYLIPQQG + phosphate
show the reaction diagram
-
-
-
?
DADEpYLIPQQG + H2O
DADEYLIPQQG + phosphate
show the reaction diagram
-
-
-
-
?
DADEpYLIPQQG + H2O
DADEYLIPQQG + phosphate
show the reaction diagram
-
a phosphopeptide substrate
-
-
?
DAEDFpYAA + H2O
DAEDFYAA + phosphate
show the reaction diagram
-
substrate of SHP-2
-
-
?
DDT-(3,5-difluoro)YDpYAA + H2O
DDT-(3,5-difluoro)YDYAA + phosphate
show the reaction diagram
-
-
-
-
?
DDTYDpYAA + H2O
DDTYDYAA + phosphate
show the reaction diagram
-
-
-
-
?
DFEDFpYAA + H2O
DFEDFYAA + phosphate
show the reaction diagram
-
substrate of SHP-2
-
-
?
difluoromethylumbelliferyl phosphate + H2O
difluoromethylumbelliferone + phosphate
show the reaction diagram
P18031
-
-
-
?
DNL-(3,5-difluoro)YpYWD + H2O
DNL-(3,5-difluoro)YYWD + phosphate
show the reaction diagram
-
-
-
-
?
DNLYpYWD + H2O
DNLYYWD + phosphate
show the reaction diagram
-
-
-
-
?
DRVpYIHPFHL + H2O
DRVYIHPFHL + phosphate
show the reaction diagram
Q64604
-
-
-
?
DWEDFpYAA + H2O
DWEDFYAA + phosphate
show the reaction diagram
-
substrate of SHP-2
-
-
?
EADTApYAA + H2O
EADTAYAA + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
EIFDFpYAA + H2O
EIFDFYAA + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
ENDpYINASL + H2O
ENDYINASL + phosphate
show the reaction diagram
-
-
-
-
?
ENDpYINASL + H2O
ENDYINASL + phosphate
show the reaction diagram
-
-
-
-
?
EphA3-phosphotyrosine + H2O
EphA3-tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
epidermal growth factor + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
epidermal growth factor receptor + H2O
? + phosphate
show the reaction diagram
-
with phosphotyrosine Tyr992
-
-
?
fatty acid binding protein + H2O
? + phosphate
show the reaction diagram
-
i.e. ppI5
-
-
?
FDEDFpYAA + H2O
FDEDFYAA + phosphate
show the reaction diagram
-
substrate of SHP-2
-
-
?
FDIDIpYAA + H2O
FDIDIYAA + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
fluorescein diphosphate + H2O
fluorescein phosphate + phosphate
show the reaction diagram
-
-
-
?
fluorescein diphosphate + H2O
?
show the reaction diagram
-
-
-
-
?
FMN + H2O
? + phosphate
show the reaction diagram
-
71.8% of the activity with 4-nitrophenyl phosphate, lung enzyme
-
-
?
FMN + H2O
?
show the reaction diagram
-
lung enzyme
-
-
-
FYDIDpYAA + H2O
FYDIDYAA + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
Gab1 tyrosine phosphate + H2O
Gab1 tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
gastrin + H2O
? + phosphate
show the reaction diagram
-
phosporylated on tyrosine
-
-
?
GESDGGpYMDMSKD + H2O
GESDGGYMDMSKD + phosphate
show the reaction diagram
-
this peptide corresponds to the sequence containing Tyr740 of the human platelet-derived growth factor receptor
-
-
?
GNGDpYMPMSPKS + H2O
GNGDYMPMSPKS + phosphate
show the reaction diagram
-
-
-
-
?
hirudin + H2O
? + phosphate
show the reaction diagram
-
hirudin from leech, phosporylated on tyrosine
-
-
?
human A431 membrane protein + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
human A431 membrane protein + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
insulin receptor phosphopeptide + H2O
insulin receptor peptide + phosphate
show the reaction diagram
-
-
-
-
?
insulin-like growth factor-1 + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
KRLIEDNE(pY)TARGQ + H2O
KRLIEDNEYTARGQ + phosphate
show the reaction diagram
-
phosphopeptide derived from autophosphorylation of mammalian tyrosine kinase Lck
-
-
?
LDEpYVATR + H2O
LDEYVATR + phosphate
show the reaction diagram
P35236
-
-
-
?
LIEDNEpYTARQGA + H2O
LIEDNEYTARQGA + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
lysozyme + H2O
? + phosphate
show the reaction diagram
-
reduced, carboxymethylated and maleylated
-
-
?
myelin basic protein + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
myelin basic protein + H2O
?
show the reaction diagram
-
-
-
-
?
myosin P-light chain + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
n-nitrophenyl phosphate + H2O
n-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
nicotinic acetylcholine receptor + H2O
? + phosphate
show the reaction diagram
-
i.e. nAChR
-
-
?
nicotinic acetylcholine receptor + H2O
?
show the reaction diagram
-
i.e. nAChR
-
-
-
NKpYGN + H2O
NKYGN + phosphate
show the reaction diagram
-
-
-
-
?
O-phospho-L-tyrosine + H2O
L-tyrosine + phosphate
show the reaction diagram
Metarhizium anisopliae, Metarhizium anisopliae CQMa102
-
-
-
-
?
p-nitrophenyl phosphate
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
P18031
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
Q0PEE2
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
-
60.3% activity compared to TRDIpYETDYYRK
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
Leishmania major Friedlin V9
-
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
Leishmania donovani 1S/Cl2D
Q0PEE2
-
-
-
?
p-nitrophenyl phosphate + H2O
p-nitrophenol + phosphate
show the reaction diagram
Metarhizium anisopliae CQMa102
-
60.3% activity compared to TRDIpYETDYYRK
-
-
?
p120ctn + H2O
120ctn + phosphate
show the reaction diagram
Mus musculus, Mus musculus C57BL/6J
-
-
-
-
?
p38 + H2O
?
show the reaction diagram
-
-
-
-
?
p38 + H2O
?
show the reaction diagram
Q16828, Q99956, Q9Y6W6
-
-
-
?
paxilin tyrosine phosphate + H2O
paxilin tyrosine + phosphate
show the reaction diagram
-
PTPRT specifically regulates paxillin phosphorylation at Tyr88 in colorectal cancer cells, substrate of PTPRT, inactive with paxilin mutant Y88F
-
-
?
phenyl phosphate + H2O
phenol + phosphate
show the reaction diagram
-
-
-
-
?
phosphocaveolin-1 + H2O
caveolin-1 + phosphate
show the reaction diagram
-
phosphorylated at Y14
-
-
?
phosphoprotein + H2O
protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Abelson interacting protein + H2O
Abelson interacting protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Abl tyrosine kinase + H2O
Abl tyrosine kinase + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Ack protein + H2O
Ack protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated actin + H2O
actin + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated adenomatous Polyposis coli-protein + H2O
adenomatous Polyposis coli-protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated alpha-actinin + H2O
alpha-actinin + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated AMP-activated protein kinase + H2O
AMP-activated protein kinase + phosphate
show the reaction diagram
-
PTPB1 is involved in AMPK regulation through its phosphorylation in a tissue-specific manner, overview, phosphorylation of the AMPK alpha subunit at Thr172
-
-
?
phosphorylated c-Kit + H2O
c-Kit + phosphate
show the reaction diagram
-
dephosphorylation occurs at tyrosines 567/569 and 719
-
-
?
phosphorylated c-MET + H2O
c-MET + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated c-MET + H2O
c-MET + phosphate
show the reaction diagram
-
PTP1B and SHP-2 are bound to the c-Met receptor to control its activity, PTP1B acts as a negative regulator, increased binding and phosphorylation of SHP-2 coincide with maximal stimulation of c-Met, therefore acting as a positive regulator
-
-
?
phosphorylated c-Src + H2O
c-Src + phosphate
show the reaction diagram
-
dephosphorylation activates c-Src
-
-
?
phosphorylated c-Src + H2O
c-Src + phosphate
show the reaction diagram
-
dephosphorylation occurs at Tyr-527
-
-
?
phosphorylated CD3 epsilon + H2O
CD3 epsilon + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Cdk2-pTpY/CycA protein + H2O
Cdk2-pTpY/CycA protein + phosphate
show the reaction diagram
P30305
-
-
-
?
phosphorylated colony-stimulating factor 1 receptor + H2O
colony-stimulating factor 1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Down syndrome cell adhesion molecule + H2O
Down syndrome cell adhesion molecule + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated E-cadherin + H2O
E-cadherin + phosphate
show the reaction diagram
Mus musculus, Mus musculus C57BL/6J
-
-
-
-
?
phosphorylated EphA2 receptor + H2O
EphA2 receptor + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated epidermal growth factor receptor + H2O
epidermal growth factor receptor + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated epidermal growth factor receptor + H2O
epidermal growth factor receptor + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated epidermal growth factor receptor + H2O
epidermal growth factor receptor + phosphate
show the reaction diagram
-
-
preferential dephosphorylation at Y1068 and Y1173
-
?
phosphorylated epidermal growth factor receptor + H2O
epidermal growth factor receptor + phosphate
show the reaction diagram
-
PTP1B negatively regulates EGF-induced signaling in HCEC cells by dephosphorylating the epidermal growth factor receptor
-
-
?
phosphorylated epidermal growth factor receptor + H2O
epidermal growth factor receptor + phosphate
show the reaction diagram
-
inactivation of EGFR
-
-
?
phosphorylated ErbB1 + H2O
ErbB1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated ErbB2 + H2O
ErbB2 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated ERK + H2O
ERK + phosphate
show the reaction diagram
-
dephosphorylation at Tyr-1175
-
-
?
phosphorylated ERK + H2O
ERK + phosphate
show the reaction diagram
-
the cleavage of STEP leads to a catalytically active form, but this cleaved form no longer binds to and dephosphorylates its substrate phosphorylated ERK
-
-
?
phosphorylated ERK1 + H2O
ERK1 + phosphate
show the reaction diagram
P35236
-
-
-
?
phosphorylated ERK2 + H2O
ERK2 + phosphate
show the reaction diagram
P35236
HePTP binds the phosphorylated tyrosine of the Erk2 peptide (pY185), Erk2 residue T183, which is phosphorylated in maximally activated Erk2, is not essential for substrate recognition and binding by HePTP
-
-
?
phosphorylated eukaryotic-initiation-factor-4G + H2O
eukaryotic-initiation-factor-4G + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated extracellular signal regulated kinase + H2O
extracellular signal regulated kinase + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated extracellular signal-regulated kinase 1 + H2O
extracellular signal-regulated kinase 1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated extracellular signal-regulated kinase 2 + H2O
extracellular signal-regulated kinase 2 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Ezrin + H2O
Ezrin + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated focal adhesion kinase + H2O
focal adhesion kinase + phosphate
show the reaction diagram
-
dephosphorylation occurs at Tyr-397, PTPD1 activity is required for focal adhesion kinase autophosphorylation and adhesion plaque stability
-
-
?
phosphorylated fragile X related + H2O
fragile X related + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Gln3 + H2O
Gln3 + phosphate
show the reaction diagram
-
Siw14, in combination with the protein kinase Npr1, regulates the intracellular localization of Gln3
-
-
?
phosphorylated HEM protein + H2O
HEM protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated hepatocyte growth factor regulated tyrosine kinase substrate + H2O
hepatocyte growth factor regulated tyrosine kinase substrate + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Hsc-70-4 + H2O
Hsc-70-4 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated IGF-I receptor + H2O
IGF-I receptor + phosphate
show the reaction diagram
-
isozyme p52shc
-
-
?
phosphorylated IGF-II mRNA-binding protein + H2O
IGF-II mRNA-binding protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated insulin receptor + H2O
insulin receptor + phosphate
show the reaction diagram
P29350
-
-
-
?
phosphorylated insulin receptor + H2O
insulin receptor + phosphate
show the reaction diagram
-
-
preferential dephosphorylation of Y1162/1163 of insulin receptor
-
?
phosphorylated insulin receptor substrate-1 + H2O
insulin receptor substrate-1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated insulin receptor substrate-2 + H2O
insulin receptor substrate-2 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated JAK2 + H2O
JAK2 + phosphate
show the reaction diagram
-
SHP2 dephosphorylates the Tyr1007 site, preventing the formation of the JAK2-Socs1 complex
-
-
?
phosphorylated Janus kinase 2 + H2O
Janus kinase 2 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated JNK + H2O
JNK + phosphate
show the reaction diagram
Q16828, Q99956, Q9Y6W6
-
-
-
?
phosphorylated Jun amino-terminal kinase + H2O
Jun amino-terminal kinase + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Lasp protein + H2O
Lasp protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Lck + H2O
Lck + phosphate
show the reaction diagram
-
component of the T cell receptor signaling pathway
-
-
?
phosphorylated mitogen-activated protein kinase + H2O
mitogen-activated protein kinase + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated mitogen-activated protein kinase Pmk1p + H2O
mitogen-activated protein kinase Pmk1p + phosphate
show the reaction diagram
Schizosaccharomyces pombe, Schizosaccharomyces pombe MI200
-
-
-
-
?
phosphorylated p130 Crk-associated substrate + H2O
p130 Crk-associated substrate + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated p130Cas + H2O
p130Cas + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated p190B Rho-GTPase-activating protein + H2O
p190B Rho-GTPase-activating protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated p38 mitogen-activated protein kinase + H2O
p38 mitogen-activated protein kinase + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated p38 mitogen-activated protein kinase + H2O
p38 mitogen-activated protein kinase + phosphate
show the reaction diagram
P35236
-
-
-
?
phosphorylated p85
p85 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated PDGF- and VEGF-receptor related + H2O
PDGF- and VEGF-receptor related + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated phospholipase Cgamma + H2O
phospholipase Cgamma + phosphate
show the reaction diagram
-
dephosphorylation occurs at Tyr-783
-
-
?
phosphorylated phospholipase Cgamma + H2O
phospholipase Cgamma + phosphate
show the reaction diagram
-
dephosphorylation occurs at Tyr-783
-
-
?
phosphorylated platelet-derived growth factor receptor + H2O
platelet-derived growth factor receptor + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated poly(A)-binding protein + H2O
poly(A)-binding protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated polychaetoid + H2O
polychaetoid + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated proline serine threonine-rich phosphatase interacting protein + H2O
proline serine threonine-rich phosphatase interacting protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated protein p85
protein p85 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated rasputin + H2O
rasputin + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated RET(C634R) oncoprotein + H2O
RET(C634R) oncoprotein + phosphate
show the reaction diagram
-
dephosphorylation at Tyr905 and Tyr1062
-
-
?
phosphorylated RET-MEN2A oncoprotein + H2O
RET-MEN2A oncoprotein + phosphate
show the reaction diagram
-
dephosphorylation at Tyr905 and Tyr1062
-
-
?
phosphorylated RET/PTC1 oncoprotein + H2O
RET/PTC1 oncoprotein + phosphate
show the reaction diagram
-
dephosphorylation at Tyr905 and Tyr1062
-
-
?
phosphorylated RhoGAP15B + H2O
RhoGAP15B + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated SCAR + H2O
SCAR + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated SH3PX1 + H2O
SH3PX1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Shc protein + H2O
Shc protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated specifically Rac1-associated protein 1 + H2O
specifically Rac1-associated protein 1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Src + H2O
Src + phosphate
show the reaction diagram
-
DEP-1 is able to dephosphorylate the inhibitory Y529 and activate Src
-
-
?
phosphorylated Src protein + H2O
Src protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Src tyrosine kinase + H2O
Src tyrosine kinase + phosphate
show the reaction diagram
-
PTPD1 associates with and activates Src tyrosine kinase
-
-
?
phosphorylated STAT1 + H2O
STAT1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated STAT1 + H2O
STAT1 + phosphate
show the reaction diagram
-
purified GST-SHP2 dephosphorylates STAT1 at both tyrosine and serine residues when immunoprecipitated phosphorylated STAT1 or phosphor-peptides corresponding to the sequence surrounding Tyr701 or Ser727 of STAT1 are used as the substrates, SHP2 negatively regulates the interferon-induced JAK/STAT pathway by dephosphorylating STAT1
-
-
?
phosphorylated STAT1c + H2O
STAT1c + phosphate
show the reaction diagram
-
-, mode of STAT activation, whereby serine-threonine phosphorylation of the cognate protein tyrosine phosphatase PTP3 results in the inhibition of its activity, shifting the phosphorylation-dephosphorylation equilibrium in favour of phosphorylation, overview
-
-
?
phosphorylated STAT3 + H2O
STAT3 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated STAT3 + H2O
STAT3 + phosphate
show the reaction diagram
-
SHP2 negatively regulates the activity of STAT3
-
-
?
phosphorylated STAT5 + H2O
STAT5 + phosphate
show the reaction diagram
-
purified SHP2 protein directly dephosphorylates STAT5 or tyrosine-phosphorylated peptides derived from STAT5
-
-
?
phosphorylated T cell antigen receptor chain zeta + H2O
T cell antigen receptor chain zeta + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated T cell antigen receptor zeta + H2O
T cell antigen receptor zeta + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated T-cell receptor-zeta subunit + H2O
T-cell receptor-zeta subunit + phosphate
show the reaction diagram
-
dephosphorylates ITAMs of the T-cell receptor-zeta subunit
-
-
?
phosphorylated TCRzeta + H2O
TCRzeta + phosphate
show the reaction diagram
-
PTPH1 dephosphorylates TCRzeta in vitro, inhibiting the downstream inflammatory signaling pathway
-
-
?
phosphorylated valosin containing protein + H2O
valosin containing protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated vascular endothelial growth factor receptor 2 + H2O
vascular endothelial growth factor receptor 2 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated vascular endothelial growth factor receptor 2 + H2O
vascular endothelial growth factor receptor 2 + phosphate
show the reaction diagram
-
dephosphorylation occurs at Tyr-1175, PTP1B binds to vascular endothelial growth factor receptor 2 cytoplasmic domain and directly dephosphorylates activated vascular endothelial growth factor receptor 2 immunoprecipitates
-
-
?
phosphorylated Vav + H2O
Vav + phosphate
show the reaction diagram
-
component of the T cell receptor signaling pathway
-
-
?
phosphorylated voltage-gated potassium channel subunit Kv2.1 + H2O
voltage-gated potassium channel subunit Kv2.1 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Y527-phosphorylated Src + H2O
Src + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated YwqD
YwqD + phosphate
show the reaction diagram
-
protein implicated in UDP-glucuronate synthesis
-
-
?
phosphorylated YwqF
YwqF + phosphate
show the reaction diagram
-
protein implicated in UDP-glucuronate synthesis
-
-
?
phosphorylated ZAP-70 + H2O
ZAP-70 + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Zap70 + H2O
Zap70 + phosphate
show the reaction diagram
-
protein-tyrosine kinase
-
-
?
phosphoserine + H2O
serine + phosphate
show the reaction diagram
-
-
-
-
?
phosphothreonine + H2O
threonine + phosphate
show the reaction diagram
-
-
-
-
?
phosphothreonine + H2O
threonine + phosphate
show the reaction diagram
-
-
-
-
?
phosphothreonine + H2O
threonine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
P30305
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
O14522, P10586, P17706, P18433, P23468, P23469, P23470, P23471, P26045, P28827, P29074, P43378, P54829, Q05209, Q06124, Q0VAE8, Q12913, Q12923, Q13332, Q15256, Q15262, Q15678, Q16825, Q16827, Q16849, Q4JDK3, Q92729, Q92932, Q99952, Q9H3S7, Q9HD43, Q9UMZ3, Q9Y2R2
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
P30307
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
best substrate
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
45.2% of the activity with 4-nitrophenyl phosphate, lung enzyme
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
lung enzyme
-
-
-
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
Mus musculus C57BL/6J
-
-
-
-
?
phosphotyrosine serum albumin + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosine serum albumin + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl casein + H2O
tyrosylcasein + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl histone + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl myelin basic protein + H2O
tyrosyl-myelin basic protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl reduced carboxyamidomethylated and maleylated lysozyme + H2O
tyrosyl-reduced carboxyamidomethylated and maleylated lysozyme + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl-casein + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl-casein + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl-casein + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
phosphotyrosyl-STAT3 + H2O
STAT3 + phosphate
show the reaction diagram
-
-, signal transducers and activator of transcription 3, STAT3, is a transcription factor that is associated with survival, proliferation, chemoresistance, and angiogenesis of tumor cells
-
-
?
platelet-derived growth factor receptor + H2O
? + phosphate
show the reaction diagram
Q06124
-
-
-
?
platelet-derived growth factor receptor + H2O
? + phosphate
show the reaction diagram
-
with phosphotyrosine Tyr1021 or Tyr1009
-
-
?
PLC-gamma1 tyrosine phosphate + H2O
PLC-gamma1 tyrosine + phosphate
show the reaction diagram
-
-
-
-
?
poly(Glu,Tyr) + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
poly(Glu,Tyr) + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
poly(Glu,Tyr) + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
protein FAK + H2O
?
show the reaction diagram
-
-
-
-
?
protein Shc + H2O
?
show the reaction diagram
-
-
-
-
?
Raytide peptide + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
RE-(3,5-difluoro)YEFpYAA + H2O
RE-(3,5-difluoro)YEFYAA + phosphate
show the reaction diagram
-
-
-
-
?
REYEFpYAA + H2O
REYEFYAA + phosphate
show the reaction diagram
-
-
-
-
?
RRISTpYAA + H2O
RRISTYAA + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
RRLIEDAEpYAARG + H2O
RRLIEDAEYAARG + phosphate
show the reaction diagram
-
-
-
-
?
SASASpYDWEF + H2O
SASASYDWEF + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
SASASpYSASA + H2O
SASASYSASA + phosphate
show the reaction diagram
-
substrate of RPTPalpha, substrate of SHP-1 and SHP-2
-
-
?
SKAP-HOM + H2O
?
show the reaction diagram
-
a cytosolic adaptor protein required for proper activation of the immune system, a bona fide Lyp substrate
-
-
?
TATEPQpYQPGEN + H2O
TATEPQYQPGEN + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
TATEPQpYQPGENL + H2O
TATEPQYQPGENL + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
TEVGKRI(pY)RLVGDKN + H2O
TEVGKRIYRLVGDKN + phosphate
show the reaction diagram
Q4JB88, -
-
-
-
?
TEVGKRI(pY)RLVGDKN + H2O
TEVGKRIYRLVGDKN + phosphate
show the reaction diagram
Sulfolobus acidocaldarius MW001
Q4JB88
-
-
-
?
TGFLTELpYVATRWY + H2O
TGFLTELYVATRWY + phosphate
show the reaction diagram
-
this peptide corresponds to the sequence containing Tyr204 of the human extracellular signal-regulated kinase
-
-
?
TRDIpYETDYYRK + H2O
TRDIYETDYYRK + phosphate
show the reaction diagram
Metarhizium anisopliae, Metarhizium anisopliae CQMa102
-
100% activity
-
-
?
TSTEPQpYQPGENL + H2O
TSTEPQYQPGENL + phosphate
show the reaction diagram
-
-
-
?
TSTEPQpYQPGENL + H2O
TSTEPQYQPGENL + phosphate
show the reaction diagram
-
this sequence contains the C-terminal phosphorylation site of c-src with phosphorylated Tyr527
-
-
?
TSTEPQpYQPGENL + H2O
TSTEPQYQPGENL + phosphate
show the reaction diagram
-
substrate of RPTPalpha
-
-
?
tyrosin kinase + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
tyrosine-phosphorylated myelin basic protein + H2O
myelin basic protein + phosphate
show the reaction diagram
-
-
-
?
tyrosine-phosphorylated Raytide + H2O
Raytide + phosphate
show the reaction diagram
-
-
-
?
WAGDDpYAA + H2O
WAGDDYAA + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
WDEDFpYAA + H2O
WDEDFYAA + phosphate
show the reaction diagram
-
substrate of SHP-2
-
-
?
WDEDFpYDWEF + H2O
WDEDFYDWEF + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
WDEDFpYRWKF + H2O
WDEDFYRWKF + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
WDEDFpYSASA + H2O
WDEDFYSASA + phosphate
show the reaction diagram
-
substrate of RPTPalpha, substrate of SHP-1 and SHP-2
-
-
?
WRKRFpYDWEF + H2O
WRKRFYDWEF + phosphate
show the reaction diagram
-
substrate of SHP-1 and SHP-2
-
-
?
YCRPESQEHPEADPGAAPpYLK + H2O
YCRPESQEHPEADPGAAYLK + phosphate
show the reaction diagram
-
YCRPESQEHPEADPGAApYLK is signal transducer and activator of transcription 3, is dephosphorylated at Y705
-
-
?
[protein]-L-tyrosine phosphate + H2O
[protein]-L-tyrosine + phosphate
show the reaction diagram
Q4JB88, -
-
-
-
?
[protein]-L-tyrosine phosphate + H2O
[protein]-L-tyrosine + phosphate
show the reaction diagram
Sulfolobus acidocaldarius MW001
Q4JB88
-
-
-
?
membrane protein 3 + H2O
? + phosphate
show the reaction diagram
-
-
-
-
?
additional information
?
-
-
inactive towards phosphoseryl histone
-
-
-
additional information
?
-
-
no hydrolysis of serine phosphate, threonine phosphate, nicotinamide adenine dinucleotide phosphate
-
-
-
additional information
?
-
-
acts specifically on phosphorylated tyrosine
-
?
additional information
?
-
-
both isozymes act only on phosphotyrosine residues
-
?
additional information
?
-
-
kinetic constants for several peptide substrates
-
?
additional information
?
-
-
PtpA, PtpB act specifically on phosphotyrosine residues
-
?
additional information
?
-
P29350
study on substrate specificity
-
?
additional information
?
-
-
study on substrate specificity, screen of peptide substrate library
-
?
additional information
?
-
Q62130
the isoforms of PRP36 may function as adapter molecules rather than as a phosphatase
-
-
-
additional information
?
-
-
PTPases regulate the ligand-induced autophosphorylation of PTK growth factor receptors, the phosphotyrosine-mediated binding s of src homology 2 (SH2)-domain-containing proteins to autophosphorylated PTK growth factor receptors and the activation state of the src family pf PTK
-
-
-
additional information
?
-
-
LMW-PTP is involved in the negative regulation of the mitogenic stimulus starting from the activated PDGF receptor. The interaction between LMW-PTP results in the dephosphorylation of the PDGF-R phosphortyrosine and a negative regulation of the mitogenic signal
-
-
-
additional information
?
-
-
protein-tyrosine phosphatases are signaling molecules that are involved in numerous cellular mechanisms such as cell growth and proliferation, cell cycle regulation, and cytoskeletal integrity
-
-
-
additional information
?
-
-
essential for virulence of the bacteria responsible for the plague
-
?
additional information
?
-
-
LAR, PTPalpha and PTP1B may act upon cell surface insulin receptors
-
?
additional information
?
-
-
physiological substrates, overview
-
?
additional information
?
-
-
possible specific substrate is p190Rho-GAP
-
?
additional information
?
-
-
enzyme activity is correlated with sperm thiol status and tyrosine phosphorylation of sperm proteins during maturation is promoted by thiol oxidation and diminished enzyme
-
-
-
additional information
?
-
-
enzyme isoform Shp2 is required for complete activation of mitogen-activated protein kinases MAPKs by brain-derived neurotropic factor
-
-
-
additional information
?
-
-
protein tyrosine phosphatase alpha regulates the activity of raft Fyn
-
-
-
additional information
?
-
-
regulation of the function of epidermal growth factor receptor in keratinocytes by its dephosphorylation
-
-
-
additional information
?
-
-
SHP-1 may regulate the tethering of receptors to the cytoskeleton and/or the extent of cross-linking of actin filaments in platelets
-
-
-
additional information
?
-
-
no substrate: phosphoeptides RRA(pS)VA, KR(pT)IRR
-
-
-
additional information
?
-
-
Cdc25 phosphatases prefer a bisanionic over a monoanionic substrate
-
-
-
additional information
?
-
-
little or no effect on the residues of phosphoserine or phosphothreonine
-
-
-
additional information
?
-
-
N-cadherin, VE-cadherin, desmoglein, alpha-catenin, beta-catenin, gamma-catenin, and alpha-actinin are not dephosphorylated by RPTPrho
-
-
-
additional information
?
-
-
no activity against phytic acid, ADP, AMP, O-phospho-L-serine or O-phospho-L-threonine
-
-
-
additional information
?
-
-
no activity on phosphothreonine substrates
-
-
-
additional information
?
-
-
phosphoserine and phosphothreonine are no substrates
-
-
-
additional information
?
-
-
activation of SPH-1 and SPH-2 is accompanied by reduced responsiveness to aggregating agents, phosphorylation of SPH-1 and SPH-2 introduces docking sites for adaptor molecules like growth factor receptor-bound protein 2 regulating further signaling to integrin alphaIIbbeta3
-
-
-
additional information
?
-
-
by modulating Src-focal adhesion kinase signaling at adhesion sites, PTPD1 promotes the cytoskeleton events that induce cell adhesion and migration
-
-
-
additional information
?
-
-
functional inactivation of the protein tyrosine phosphatase DEP-1 leads to increased endothelial cell proliferation and failure of vessels to remodel and branch
-
-
-
additional information
?
-
-
human LMW-PTP is critical in the regulation of mitogenic signalling and Rho-mediated cytoskeletal rearrangements after platelet derived growth factor stimulation
-
-
-
additional information
?
-
-
PTP is an element of the abscisic acid signaling pathway that leads to stomatal closure
-
-
-
additional information
?
-
-
PTP-H2 functions as an inhibitor of phagocytosis, PTP-H2 mediates cell death of infected Sf-21 cells, expression of PTP-H2 triggers mitochondrial membrane depolarisation and caspase-dependent apoptosis
-
-
-
additional information
?
-
-
PTP-PEST most likely also participates in regulating osteoclast differentiation and adhesion to bone matrix
-
-
-
additional information
?
-
-
PTPalpha is required for stem cell factor-stimulated Src family kinase activation and signaling, and for mast cell migration
-
-
-
additional information
?
-
-
SHP-1 is a negative regulator of osteoclastogenic signalling
-
-
-
additional information
?
-
-
SHP-2, MKP-1, LAR, and PTEN are targets of platelet-derived growth factor-induced reversible oxidation
-
-
-
additional information
?
-
-
phospho-p38 mitogen-activated protein kinase and Akt are not dephosphorylated
-
-
-
additional information
?
-
-
DEP-1 is a positive regulator of VEGF-mediated Src and Akt activation and endothelial cell survival
-
-
-
additional information
?
-
-
HePTP plays a role in regulating the level of p38 MAPK phosphorylation in B-lymphocytes, HePTP can be phosphorylated by PKA, which inactivates the phosphatase and causes it to release p38 MAPK into the cytoplasm
-
-
-
additional information
?
-
-
PPM displays little activity toward P-Ser/Thr histones
-
-
-
additional information
?
-
-
PTPN4 does not dephosphorylate Lck at tyrosine residue 394
-
-
-
additional information
?
-
O00167
ED-Eya2 is bifunctional acting as protein tyrosine phosphatase and as transcription factor. The transcriptional activity of Eya proteins is regulated by a dephosphorylating activity within its Eya domain, structure-function analysis, overview
-
-
-
additional information
?
-
-
isozyme p52shc associates with the growth factor receptor-bound protein-2, Grb2. Overexpression of isozyme p66shc impaires IGF-I-stimulated p52shc tyrosine phosphorylation and p52shc-Grb2 association. Isozyme p66shc inhibits IGF-I signal transduction via competitively inhibiting the binding of Src homology 2 domain-containing SHP-2 to SHP substrate-1, leading to the disruption of SHPS-1/SHP-2/Src/p52shc complex formation, an event that is essential for p52shc phosphorylation and Grb2 recruitment, overview. p66shc inhibits IGF-I signal transduction via impairing membrane recruitment of Grb2
-
-
-
additional information
?
-
-
protein tyrosine phosphatase 1B, PTP1B, is an intracellular non-receptor type PTP
-
-
-
additional information
?
-
-
STATc becomes tyrosine phosphorylated and accumulates in the nucleus when Dictyostelium cells are exposed to the prestalk cell inducer Differentiation inducing factor 1, DIF-1, or are subjected to hyperosmotic stress
-
-
-
additional information
?
-
-
formation and structure of a transition state analogue for the first catalytic step comprising a ternary complex between the catalytic cysteine of PTP1B, vanadate, and the peptide DADEYL, a fragment of a physiological substrate, overview. The equatorial vanadate oxygen atoms bind to the P-loop, and the apical positions are occupied by the peptide tyrosine oxygen and by the PTP1B cysteine sulfur atom. The vanadate assumes a trigonal bipyramidal geometry in both transition state analogue structures, with very similar apical O-O distances, denoting similar transition states for both phosphoryl transfer steps
-
-
-
additional information
?
-
-
in the YopH PTP catalytic mechanism, the active site Cys403 sits at the bottom of the pTyr-binding pocket, i.e., the active site, such that its Sgamma atom is poised 3 A from the phosphorus atom of the substrate ready for nucleophilic attack
-
-
-
additional information
?
-
-
the enzyme contains a Cys(X5)Arg catalytic domain
-
-
-
additional information
?
-
-
PTEN phosphoprotein phosphatase catalysis of phosphoprotein dephosphorylation follows a two-step mechanism with Cys124 transiently phosphorylated to form the phosphoenzyme intermediate
-
-
-
additional information
?
-
-
SynPTP displays catalytic activity towards all tyrosyl-phosphorylated proteins, but fails to dephosphorylate the same serylphosphorylated substrates, SynPTP functions as a protein tyrosine phosphatase not as a dual-specific phosphatase
-
-
-
additional information
?
-
-
no activity with DADEpYLIPQQG, poor activity with 4-nitrophenyl phosphate
-
-
-
additional information
?
-
-
Ser380, Thr382 and Thr383 C-terminal tail residues do not affect the recruitment of the WPD-loop into the active site to participate in the phosphoprotein dephosphorylation reaction, catalytic mechanism of PTEN phosphoprotein phosphatase activity, overview. The phosphoPTEN protein is not the cysteinyl phosphoenzyme intermediate formed by transient phosphorylation of Cys124 in the course of phosphopeptide dephosphorylation reaction. PTEN can adopt the closed conformation to allow Asp92 to participate in catalysis when it dephosphorylates the physiological protein substrates such as FAK and Shc in cells
-
-
-
additional information
?
-
-
substrate specificity analysis using a trapping mutant of the phosphatase, which is a point mutation that maintains specificity but does not allow detachment of the phosphate, overview. The enzyme is also active on 4-nitrophenyl phosphate, but is not active on GRB2
-
-
-
additional information
?
-
-
substrate specificity of lymphoid-specific tyrosine phosphatase, identification of consensus sequence motifs for Lyp substrate recognition using an inverse alanine scanning combinatorial library approach, molecular determinants and molecular basis for Lyp substrate recognition, crystal structure analysis, overview
-
-
-
additional information
?
-
-
the enzyme is also active on 4-nitrophenyl phosphate
-
-
-
additional information
?
-
-
the PTP1B catalytic domain has modest preference for acidic residues on both sides of phosphotyrosine, is highly active toward multiply phosphorylated peptides, but disfavors basic residues at any position, a Gly at the phosphotyrosine-1 position, or a Pro at the pY-/-1 position. By contrast, SHP-1 and SHP-2 share similar but much narrower substrate specificities, with a strong preference for acidic and aromatic hydrophobic amino acids on both sides of the phosphotyrosine residue. An efficient SHP-1/2 substrate generally contains two or more acidic residues on the N-terminal side and one or more acidic residues on the C-terminal side of pY but no basic residues, substrate specificities of the protein tyrosine phosphatases PTP1B, RPTPalpha, SHP-1, and SHP-2, and reported PTP1B, SHP-1, and SHP-2 substrates and their dephosphorylation sites, overview. The catalytic domain of RPTPalpha has very weak sequence specificity and is approximately 2 orders of magnitude less active than the other three enzyme variants
-
-
-
additional information
?
-
Mus musculus C57BL/6J
-
N-cadherin, VE-cadherin, desmoglein, alpha-catenin, beta-catenin, gamma-catenin, and alpha-actinin are not dephosphorylated by RPTPrho
-
-
-
additional information
?
-
Metarhizium anisopliae CQMa102
-
no activity against phytic acid, ADP, AMP, O-phospho-L-serine or O-phospho-L-threonine
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
nicotinic acetylcholine receptor + H2O
?
show the reaction diagram
-
i.e. nAChR
-
-
-
paxilin tyrosine phosphate + H2O
paxilin tyrosine + phosphate
show the reaction diagram
-
PTPRT specifically regulates paxillin phosphorylation at Tyr88 in colorectal cancer cells
-
-
?
phosphocaveolin-1 + H2O
caveolin-1 + phosphate
show the reaction diagram
-
phosphorylated at Y14
-
-
?
phosphorylated alpha-actinin + H2O
alpha-actinin + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated AMP-activated protein kinase + H2O
AMP-activated protein kinase + phosphate
show the reaction diagram
-
PTPB1 is involved in AMPK regulation through its phosphorylation in a tissue-specific manner, overview
-
-
?
phosphorylated CD3 epsilon + H2O
CD3 epsilon + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated epidermal growth factor receptor + H2O
epidermal growth factor receptor + phosphate
show the reaction diagram
-
inactivation of EGFR
-
-
?
phosphorylated Gln3 + H2O
Gln3 + phosphate
show the reaction diagram
-
Siw14, in combination with the protein kinase Npr1, regulates the intracellular localization of Gln3
-
-
?
phosphorylated IGF-I receptor + H2O
IGF-I receptor + phosphate
show the reaction diagram
-
isozyme p52shc
-
-
?
phosphorylated Lck + H2O
Lck + phosphate
show the reaction diagram
-
component of the T cell receptor signaling pathway
-
-
?
phosphorylated p130 Crk-associated substrate + H2O
p130 Crk-associated substrate + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated STAT1c + H2O
STAT1c + phosphate
show the reaction diagram
-
mode of STAT activation, whereby serine-threonine phosphorylation of the cognate protein tyrosine phosphatase PTP3 results in the inhibition of its activity, shifting the phosphorylation-dephosphorylation equilibrium in favour of phosphorylation, overview
-
-
?
phosphorylated T cell antigen receptor zeta + H2O
T cell antigen receptor zeta + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated valosin containing protein + H2O
valosin containing protein + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Vav + H2O
Vav + phosphate
show the reaction diagram
-
component of the T cell receptor signaling pathway
-
-
?
phosphorylated Y527-phosphorylated Src + H2O
Src + phosphate
show the reaction diagram
-
-
-
-
?
phosphorylated Zap70 + H2O
Zap70 + phosphate
show the reaction diagram
-
protein-tyrosine kinase
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
show the reaction diagram
-
lung enzyme
-
-
-
phosphotyrosyl-STAT3 + H2O
STAT3 + phosphate
show the reaction diagram
-
signal transducers and activator of transcription 3, STAT3, is a transcription factor that is associated with survival, proliferation, chemoresistance, and angiogenesis of tumor cells
-
-
?
[protein]-L-tyrosine phosphate + H2O
[protein]-L-tyrosine + phosphate
show the reaction diagram
Q4JB88, -
-
-
-
?
[protein]-L-tyrosine phosphate + H2O
[protein]-L-tyrosine + phosphate
show the reaction diagram
Sulfolobus acidocaldarius MW001
Q4JB88
-
-
-
?
FMN + H2O
?
show the reaction diagram
-
lung enzyme
-
-
-
additional information
?
-
Q62130
the isoforms of PRP36 may function as adapter molecules rather than as a phosphatase
-
-
-
additional information
?
-
-
PTPases regulate the ligand-induced autophosphorylation of PTK growth factor receptors, the phosphotyrosine-mediated binding s of src homology 2 (SH2)-domain-containing proteins to autophosphorylated PTK growth factor receptors and the activation state of the src family pf PTK
-
-
-
additional information
?
-
-
LMW-PTP is involved in the negative regulation of the mitogenic stimulus starting from the activated PDGF receptor. The interaction between LMW-PTP results in the dephosphorylation of the PDGF-R phosphortyrosine and a negative regulation of the mitogenic signal
-
-
-
additional information
?
-
-
protein-tyrosine phosphatases are signaling molecules that are involved in numerous cellular mechanisms such as cell growth and proliferation, cell cycle regulation, and cytoskeletal integrity
-
-
-
additional information
?
-
-
essential for virulence of the bacteria responsible for the plague
-
?
additional information
?
-
-
LAR, PTPalpha and PTP1B may act upon cell surface insulin receptors
-
?
additional information
?
-
-
physiological substrates, overview
-
?
additional information
?
-
-
possible specific substrate is p190Rho-GAP
-
?
additional information
?
-
-
enzyme activity is correlated with sperm thiol status and tyrosine phosphorylation of sperm proteins during maturation is promoted by thiol oxidation and diminished enzyme
-
-
-
additional information
?
-
-
enzyme isoform Shp2 is required for complete activation of mitogen-activated protein kinases MAPKs by brain-derived neurotropic factor
-
-
-
additional information
?
-
-
protein tyrosine phosphatase alpha regulates the activity of raft Fyn
-
-
-
additional information
?
-
-
regulation of the function of epidermal growth factor receptor in keratinocytes by its dephosphorylation
-
-
-
additional information
?
-
-
SHP-1 may regulate the tethering of receptors to the cytoskeleton and/or the extent of cross-linking of actin filaments in platelets
-
-
-
additional information
?
-
-
activation of SPH-1 and SPH-2 is accompanied by reduced responsiveness to aggregating agents, phosphorylation of SPH-1 and SPH-2 introduces docking sites for adaptor molecules like growth factor receptor-bound protein 2 regulating further signaling to integrin alphaIIbbeta3
-
-
-
additional information
?
-
-
by modulating Src-focal adhesion kinase signaling at adhesion sites, PTPD1 promotes the cytoskeleton events that induce cell adhesion and migration
-
-
-
additional information
?
-
-
functional inactivation of the protein tyrosine phosphatase DEP-1 leads to increased endothelial cell proliferation and failure of vessels to remodel and branch
-
-
-
additional information
?
-
-
human LMW-PTP is critical in the regulation of mitogenic signalling and Rho-mediated cytoskeletal rearrangements after platelet derived growth factor stimulation
-
-
-
additional information
?
-
-
PTP is an element of the abscisic acid signaling pathway that leads to stomatal closure
-
-
-
additional information
?
-
-
PTP-H2 functions as an inhibitor of phagocytosis, PTP-H2 mediates cell death of infected Sf-21 cells, expression of PTP-H2 triggers mitochondrial membrane depolarisation and caspase-dependent apoptosis
-
-
-
additional information
?
-
-
PTP-PEST most likely also participates in regulating osteoclast differentiation and adhesion to bone matrix
-
-
-
additional information
?
-
-
PTPalpha is required for stem cell factor-stimulated Src family kinase activation and signaling, and for mast cell migration
-
-
-
additional information
?
-
-
SHP-1 is a negative regulator of osteoclastogenic signalling
-
-
-
additional information
?
-
-
SHP-2, MKP-1, LAR, and PTEN are targets of platelet-derived growth factor-induced reversible oxidation
-
-
-
additional information
?
-
O00167
ED-Eya2 is bifunctional acting as protein tyrosine phosphatase and as transcription factor. The transcriptional activity of Eya proteins is regulated by a dephosphorylating activity within its Eya domain, structure-function analysis, overview
-
-
-
additional information
?
-
-
isozyme p52shc associates with the growth factor receptor-bound protein-2, Grb2. Overexpression of isozyme p66shc impaires IGF-I-stimulated p52shc tyrosine phosphorylation and p52shc-Grb2 association. Isozyme p66shc inhibits IGF-I signal transduction via competitively inhibiting the binding of Src homology 2 domain-containing SHP-2 to SHP substrate-1, leading to the disruption of SHPS-1/SHP-2/Src/p52shc complex formation, an event that is essential for p52shc phosphorylation and Grb2 recruitment, overview. p66shc inhibits IGF-I signal transduction via impairing membrane recruitment of Grb2
-
-
-
additional information
?
-
-
protein tyrosine phosphatase 1B, PTP1B, is an intracellular non-receptor type PTP
-
-
-
additional information
?
-
-
STATc becomes tyrosine phosphorylated and accumulates in the nucleus when Dictyostelium cells are exposed to the prestalk cell inducer Differentiation inducing factor 1, DIF-1, or are subjected to hyperosmotic stress
-
-
-
additional information
?
-
-
PTEN phosphoprotein phosphatase catalysis of phosphoprotein dephosphorylation follows a two-step mechanism with Cys124 transiently phosphorylated to form the phosphoenzyme intermediate
-
-
-
additional information
?
-
-
SynPTP displays catalytic activity towards all tyrosyl-phosphorylated proteins, but fails to dephosphorylate the same serylphosphorylated substrates, SynPTP functions as a protein tyrosine phosphatase not as a dual-specific phosphatase
-
-
-
METALS and IONS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
Ba2+
-
42.5% increase of activity at 20 mM
Ba2+
Q72JF6
activates the recombinant enzyme
Ca2+
Q72JF6
activates the recombinant enzyme
Ca2+
-
increases the enzyme activity
Ca2+
-
4-6fold increase of activity
Ca2+
-
activation
Cu2+
-
or Mn2+, Zn2+, required
Mg2+
Q72JF6
activates the recombinant enzyme
Mg2+
-
Mg2+ or Mn2+ required
Mg2+
-
4-6fold increase of activity
Mg2+
-
no effect
Mg2+
-
activation
Mn2+
-
or Cu2+, Zn2+, required, Km-value 0.274 mM
Mn2+
-
9.2% increase of activity at 20 mM
Mn2+
-
Mn2+ supports catalysis
Mn2+
Q72JF6
activates 3fold at 5 mM, recombinant enzyme
Mn2+
-
Mg2+ or Mn2+ required
Mn2+
-
4-6fold increase of activity
Mn2+
-
no effect
NaF
-
activation
Ni2+
Q72JF6
activates the recombinant enzyme
Zn2+
-
or Cu2+, Mn2+, required
Zn2+
Q9S427
contains 1.79 mol of Zn2+ per mole
Mn2+
-
activation
additional information
-
not activating: Mg2+, Ca2+
additional information
-
contains two metal ions per asymmetric unit, crystallization data
additional information
-
Mg2+, Co2+, or Ca2+ have no effect on activity
additional information
-
the inclusion of Mg2+, Ni2+, Ca2+, and Cu2+ along with Mn2+ has little effect on activity relative to that observed with Mn2+ alone
additional information
-
divalent cations Zn2+, Ca2+, Mg2+, and Mn2+ have little or no negative effect on activity
additional information
-
activity not dependent on divalent cations
INHIBITORS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
((1E)-2-nitroprop-1-en-1-yl)benzene
-
50% inhibition at 0.023 mM in absence of 2-mercaptoethanol, at 0.515 mM in presence of 1 mM 2-mercaptoethanol
((2-bromo-4-((((2E)-3-phenylprop-2-en-1-yl)sulfanyl)methyl)phenyl)carbonyl)phosphonate
P18031
50% inhibiton at 810 nM for wild-type, at 1290 nM for mutant S295F
((2-bromo-4-(((4-chlorobenzyl)thio)methyl)phenyl)(difluoro)methyl)phosphonate
P18031
50% inhibiton at 285 nM for wild-type, at 1644 nM for mutant S295F
((2-phenyl-2-(phenylcarbonyl)propane-1,3-diyl)bis(benzene-4,1-diyl(difluoromethanediyl)))bis(phosphonate)
P18031
50% inhibiton at 82 nM for wild-type, at 399 nM for mutant S295F
((4-((((3'-(acetylsulfamoyl)biphenyl-4-yl)methyl)sulfanyl)methyl)-2-bromophenyl)(difluoro)methyl)phosphonate
P18031
50% inhibiton at 2.2 nM for wild-type, at 11 nM for mutant S295F
((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(difluoro)methyl)phosphonate
P18031
50% inhibiton at 47 nM for wild-type, at 260 nM for mutant S295F
((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(fluoro)methyl)phosphonate
P18031
50% inhibiton at 570 nM for wild-type, at 830 nM for mutant S295F
((4-((4E)-2-(1H-benzotriazol-1-yl)-2,5-diphenylpent-4-en-1-yl)phenyl)(difluoro)methyl)phosphonic acid
-
50% inhibition at 109 nM for isoform PTP-1B, at 95 nM for isoform TCPTP
((E)-2-nitrovinyl)benzene
-
i.e. trans-beta-nitrostyrene, slow-binding inhibitor, acting as a pY mimetic and binding to the enzyme active site to form an initial noncovalent E*I complex, followed by nucleophilic attack on the nitrostyrene nitro group by C215 of enzyme to form a reversible, covalent adduct. 50% inhibition at 0.0025 mM in absence of 2-mercaptoethanol, at 0.4 mM in presence of 1 mM 2-mercaptoethanol
(1-benzyl-3-methyl-2,3-dihydro-1H-imidazol-2-yl)(chloro)gold
-
i.e. [(BzMeIm)AuICl]
(2alpha,3alpha)-2,3-dihydroxyolean-12-en-28-oic acid
-
-
(2beta,3beta)-2,3-dihydroxyolean-12-en-28-oic acid
-
-
(2E)-1-(2'-hydroxyphenyl)-3-(1-naphthyl)-2-propen-1-one
-
76% inhibition at 0.025 mM
(2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-1-(2,4-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
20% inhibition at 0.025 mM
(2E)-1-(2,4-dimethoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
-
(2E)-1-(2,5-dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one
-
58% inhibition at 0.025 mM
(2E)-1-(2,5-dimethoxyphenyl)-3-(naphth-1-yl)-2-propen-1-one
-
46% inhibition at 0.025 mM
(2E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(3-nitrophenyl)prop-2-en-1-one
-
8% inhibition at 0.025 mM
(2E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
16% inhibition at 0.025 mM
(2E)-1-(2-hydroxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
26% inhibition at 0.025 mM
(2E)-1-(3,4-dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one
-
-
(2E)-1-(3,4-dimethoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
68.5% inhibition at 0.025 mM
(2E)-1-(3-aminophenyl)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(3-hydroxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
20% inhibition at 0.025 mM
(2E)-1-(3-methoxy-4-hydroxyphenyl)-3-(2-naphthyl)-2-propen-1-one
-
-
(2E)-1-(3-methoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
18.5% inhibition at 0.025 mM
(2E)-1-(4-aminophenyl)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(4-bromophenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
25% inhibition at 0.025 mM
(2E)-1-(4-bromophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
11% inhibition at 0.025 mM
(2E)-1-(4-hydroxy-3-methoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one
-
39% inhibition at 0.025 mM
(2E)-1-(4-methoxyphenyl)-3-(naphthalen-1-yl)prop-2-en-1-one
-
18% inhibition at 0.025 mM
(2E)-1-[3-(benzyloxy)phenyl]-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one
-
8% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2,5-dimethoxyphenyl)prop-2-en-1-one
-
9% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
18% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(3-nitrophenyl)prop-2-en-1-one
-
26% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-bromophenyl)prop-2-en-1-one
-
14% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
-
20% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
6% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-(4-nitrophenyl)prop-2-en-1-one
-
19.5% inhibition at 0.025 mM
(2E)-3-(1,3-benzodioxol-5-yl)-1-phenylprop-2-en-1-one
-
-
(2E)-3-(3,4-dichlorophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-chlorophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(3-chlorophenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one
-
13% inhibition at 0.025 mM
(2E)-3-(3-nitrophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-(5-bromo-2,4-dihydroxyphenyl)-1-[4-methoxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(3-[[(methoxycarbonyl)sulfanyl]amino]phenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(4-butoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[2-(dimethylamino)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[2-(piperidin-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[2-[di(prop-2-en-1-yl)amino]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-(3-methylbut-3-en-2-yl)-4-[(3-methylbut-2-en-1-yl)oxy]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-(dimethylamino)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-(piperidin-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[3-[di(prop-2-en-1-yl)amino]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(1H-pyrazol-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(dimethylamino)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(morpholin-4-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-(piperidin-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(prop-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-methoxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-methoxy-3-(prop-2-en-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-[(3-methylbut-2-en-1-yl)oxy]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-[(4-methylphenyl)sulfonyl]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[4-[di(prop-2-en-1-yl)amino]phenyl]prop-2-en-1-one
-
-
(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)-1-[6-(dimethylamino)-1,3-benzodioxol-5-yl]prop-2-en-1-one
-
-
(2E)-3-(naphthalen-1-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(naphthalen-1-yl)-1-(3-nitrophenyl)prop-2-en-1-one
-
12% inhibition at 0.025 mM
(2E)-3-(naphthalen-1-yl)-1-(4-nitrophenyl)prop-2-en-1-one
-
18% inhibition at 0.025 mM
(2E)-3-(naphthalen-1-yl)-1-phenylprop-2-en-1-one
-
37% inhibition at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
9% activation at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-(3-nitrophenyl)prop-2-en-1-one
-
16% inhibition at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one
-
11% inhibition at 0.025 mM
(2E)-3-(naphthalen-2-yl)-1-phenylprop-2-en-1-one
-
12% inhibition at 0.025 mM
(2E)-3-[2,4-dimethoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
a semisynthetic licochalcone A derivative
(2E)-3-[2,4-dimethoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
a semisynthetic licochalcone A derivative
(2E)-3-[4-hydroxy-2-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
a semisynthetic licochalcone A derivative
(2E)-3-[4-hydroxy-2-methoxy-5-(3-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
(2E)-3-[5-bromo-2-hydroxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl]-1-[4-methoxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-[5-bromo-2-methoxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl]-1-[4-hydroxy-3-(3-methylbut-3-en-2-yl)phenyl]prop-2-en-1-one
-
-
(2R)-2-benzyl-3-[2,6-dibromo-4-(6-bromo-5a,11a-dihydrobenzo[b]naphtho[2,3-d]furan-11-yl)phenyl]propanoic acid
-
-
(3S,6S,9R)-3,6-dimethyl-9-[(R)-phenyl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(3S,6S,9R,12R)-3,6,9-trimethyl-12-[(R)-phenyl(phenylamino)methyl]-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
-
-
(3S,9R)-3-(4-hydroxybenzyl)-9-[(R)-phenyl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)benzyl)phosphonate
P18031
50% inhibiton at 3260 nM for wild-type, at 5030 nM for mutant S295F
(4-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl]phenyl)methaneseleninic acid
-
inactivates the PTPs, e.g. YopH, by covalent modification, binds at the active site Cys403, kinetics, overview
(4aS,6aS,6bR,13aR)-10-acetyl-2,2,6a,6b,9,9,13a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-10-hexanoyl-2,2,6a,6b,9,9,13a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-11-amino-2,2,6a,6b,9,9,13a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,13,13a,13b,14,15b-hexadecahydropiceno[3,2-d][1,3]thiazole-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,13,13a,13b,14,15b-hexadecahydropiceno[2,3-d][1,2]oxazole-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-10-(pyridin-3-ylcarbonyl)-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-10-(pyridin-4-ylcarbonyl)-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,13aR)-2,2,6a,6b,9,9,13a-heptamethyl-10-phenyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15b-octadecahydro-4aH-chryseno[1,2-f]indazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-11-amino-2,2,6a,6b,9,9,14a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,11,14a-octamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,14a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,14a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
P24666
no inhibition of LMW-PTP isozymes, but 20% inhibition of PTP-B1 at 0.02 mM
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,14a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinoxaline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,14aR)-2,2,6a,6b,9,9,14a-heptamethyl-11-(methylamino)-1,3,4,5,6,6a,6b,7,8,8a,9,14,14a,14b,15,16b-hexadecahydrochryseno[1,2-g]quinazoline-4a(2H)-carboxylic acid
-
-
(4aS,6aS,6bR,15aR)-2,2,6a,6b,9,9,15a-heptamethyl-1,2,3,4,5,6,6a,6b,7,8,8a,9,10,15,15a,15b,16,17b-octadecahydro-4aH-chryseno[2,1-b]carbazole-4a-carboxylic acid
-
-
(4aS,6aS,6bR,16aR)-2,2,6a,6b,9,9,16a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,16,16a,16b,17,18b-hexadecahydrochryseno[1,2-b]phenazine-4a(2H)-carboxylic acid
-
-
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
P18031
-
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
P18031
-
(6R)-6-[(R)-phenyl(phenylamino)methyl]-1,4-diazepane-2,5-dione
-
-
(7bS,9R,13bR,15R)-7-amino-9-(hydroxymethyl)-10,13-dioxo-2,3,3a,3b,4,5,6,7,7a,7b,9,10,13,13b-tetradecahydro-1H-6,8-methanobenzo[h]imidazo[1,2-a]pyrido[3,2-c][1,5]naphthyridine-15-carbonitrile
P30304, P30305, P30307
inhibits Cdc25B modestly
(7bS,9R,13bR,15S)-7-amino-15-hydroxy-9-(hydroxymethyl)-2,3,3a,3b,4,5,6,7,7a,7b,9,13b-dodecahydro-1H-6,8-methanobenzo[h]imidazo[1,2-a]pyrido[3,2-c][1,5]naphthyridine-10,13-dione
P30304, P30305, P30307
-
(9R)-9-[(R)-furan-2-yl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(9R)-9-[(R)-phenyl(phenylamino)methyl]-1,4,7-triazecane-2,5,8-trione
-
-
(difluoro(4-((4E)-2-((4-fluorophenyl)carbonyl)-2-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-5-phenylpent-4-en-1-yl)phenyl)methyl)phosphonic acid
-
50% inhibition at 163 nM for PTP-1B wild-type, at 1903 nM for PTP-1B mutant L119V, and at 1600 nM for isoform TCPTP wild-type and 138 nM for TCPTP mutant V121L
(difluoro[4-[(2,2,2-trifluoroethyl)carbamoyl]phenyl]methyl)phosphonic acid
-
-
(difluoro[4-[(2-fluorophenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
-
(difluoro[4-[(2-phenylethyl)carbamoyl]phenyl]methyl)phosphonic acid
-
-
(difluoro[4-[(3-fluorophenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
-
(difluoro[4-[(4-fluorophenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
-
(difluoro[4-[(phenylamino)methyl]phenyl]methyl)phosphonic acid
-
-
(difluoro[4-[2-oxo-2-(phenylamino)ethyl]phenyl]methyl)phosphonic acid
-
-
(difluoro[4-[methyl(phenyl)carbamoyl]phenyl]methyl)phosphonic acid
-
-
(E)-N-(4,5-diphenyl-1,3-thiazol-2-yl)-2-naphthalen-2-ylethenesulfonamide
-
-
(E)-N-[4-(4-chlorophenyl)-5-propyl-1,3-thiazol-2-yl]-2-(3,4-dichlorophenyl)ethenesulfonamide
-
-
(Z)-2-(2-(5-(N-(4-chloro-3-(trifluoromethyl)benzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(2-carboxyphenyl)hydrazono)-2-oxoindoline-5-carboxylic acid
-
-
(Z)-3-(2-(2-nitrophenyl)hydrazono)-2-oxoindoline-5-sulfonic acid
-
NSC-117199
(Z)-3-(2-(3-carboxyphenyl)hydrazono)-2-oxoindoline-5-carboxylic acid
-
-
(Z)-3-(2-(5-(4-chlorobenzylcarbamoyl)-2-oxoindolin-3-ylidene)-hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(2,4-dichlorophenethyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(2-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(3-chloro-4-fluorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(3-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-chloro-3-(trifluoromethyl)benzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-fluorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-3-(2-(5-(N-(4-methylbenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(2-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(4-chloro-3-(trifluoromethyl)benzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(4-chlorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-(4-fluorobenzyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic acid
-
-
(Z)-4-(2-(5-(N-benzylsulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl) benzoic acid
-
-
([2-bromo-4-(3-oxo-2,3-diphenylpropyl)phenyl](difluoro)methyl)phosphonic acid
P30304, P30305, P30307
-
1,3-difluoro-2-[(E)-2-nitroethenyl]benzene
-
50% inhibition at 0.0048 mM in absence of 2-mercaptoethanol, at 0.34 mM in presence of 1 mM 2-mercaptoethanol
1-(2,6-dihydroxy-4-methoxy-3-methylphenyl)ethanone
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
1-ethyl-6-methyl-3-phenyl-1H-pyrimido(5,4-e)(1,2,4)triazine-5,7-dione
-
covalent mode of action
1-methoxy-4-((E)-2-nitrovinyl)benzene
-
50% inhibition at 0.0045 mM in absence of 2-mercaptoethanol, at 0.27 mM in presence of 1 mM 2-mercaptoethanol
1-methyl-4-((E)-2-nitrovinyl)benzene
-
50% inhibition at 0.003 mM in absence of 2-mercaptoethanol, at 0.225 mM in presence of 1 mM 2-mercaptoethanol
1-p-Bromotetramisole oxalate
-
tetramizole no effect
16alphaH,17-isovaleryloxy-ent-kauran-19-oic acid
-
diterpenoid isolated from Acanthopanax koreanum, 50% inhibition at 0.007 mM, noncompetitive
19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid
-
-
2',4'-dihydroxy-1,1'-biphenyl
P24666
-
2,2-dioxo-2,3-dihydro-2-OMEGA-16-benzo (1,2,3)oxathiazole-6-carboxylic acid (5-phenylsulfanyl-1H-benzoimidazol-2-ylmethyl)-amide
-
competitive, noncovalent mode of action
2,4-dihydroxy-6-methylbenzoic acid
-
45% inhibition of PTPB1 at 0.178 mM
2,4-dimethoxy-1-((E)-2-nitrovinyl)benzene
-
50% inhibition at 0.028 mM in absence of 2-mercaptoethanol, at 0.390 mM in presence of 1 mM 2-mercaptoethanol
2,5-dihydroxy-3-[7-(2-methylbenzyl)-1H-indol-3-yl]cyclohexa-2,5-diene-1,4-dione
-
-
2,5-dihydroxy-3-[7-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]cyclohexa-2,5-diene-1,4-dione
-
-
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
P18031
i.e. OATP
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
P18031
-
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
P18031
-
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
P18031
-
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
P18031
-
2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-hydroxybenzoic acid
-
36% residual activity at 0.1 mM; 3% residual activity at 0.1 mM; 7% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
2-(4-hydroxyphenyl)-3-[(3,4-dihydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
2-(4-hydroxyphenyl)-3-[(4-carboxy-3-hydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid
P18031
-
2-(oxalyl-amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid
P18031
-
2-(oxalyl-amino)-4,7-dihydro-5H-thieno[2,3-c]thiopyran-3-carboxylic acid
-
-
2-carboperoxybenzoate
-
complete inhibition at 150 mM
2-chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
36% residual activity at 0.1 mM; 46% residual activity at 0.1 mM; 95% residual activity at 0.1 mM; 98% residual activity at 0.1 mM
2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
37% residual activity at 0.1 mM; 77% residual activity at 0.1 mM; 88% residual activity at 0.1 mM; 91% residual activity at 0.1 mM
2-hydroperoxytetrahydrofuran
-
inactivation by 2-hydroperoxytetrahydrofuran (0.05 mM, 10 min) is reversed upon reaction of the enzyme with dithiothreitol (54% return of activity, following treatment with 100 mM dthiothreitol for 1 h)
24-hydroxyursolic acid
-
-
28-(10-decanoic)-oleanolic acid
-
-
28-(12-dodecanoic)-oleanolic acid
-
-
28-(2-acetic)-oleanolic acid
-
-
28-(4-butyric)-oleanolic acid
-
-
28-(6-hexanoic)-oleanolic acid
-
-
28-(8-octanoic)-oleanolic acid
-
-
28-(glycine)-oleanolic acid amide
-
-
28-(L-glutamic acid)-oleanolic acid amide
-
-
28-(L-phenylalanine)-oleanolic acid amide
-
-
28-(p-carboxyphenyl)-oleanolic acid amide
-
-
28-[4-butyric((R)-1-carboxy-phenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric((S)-1-carboxy-3-indole-ethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric((S)-1-carboxy-5-imidazole-ethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric((S)-1-carboxy-methylthioethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric((S)-1-carboxy-phenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-2,3-dimethoxyphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-3,4-dimethoxyphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-3,4-oxymethyleneoxyphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-3,5-dimethoxyphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-m-chlorophenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-m-methoxyphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-o-chlorophenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-o-methoxyphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-o-methylphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-p-chlorophenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-p-fluorophenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-p-methoxyphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-p-methylphenylethyl)-amide]-DELTA12-oleanene
-
-
28-[4-butyric(1-carboxy-p-nitrophenylethyl)-amide]-DELTA12-oleanene
-
-
2alpha,3alpha,19alpha,23-tetrahydroxyurs-12-en-28-oic acid
-
50% inhibition at 0.0421 mM
2beta,3beta-2,3-dihydroxyolean-12-en-28-oic acid
-
-
3',4'-dihydroxy-1,1'-biphenyl
P24666
no inhibition of LMW-PTP isozymes, but 5% inhibition of PTP-B1 at 0.02 mM
3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-(1,3-thiazol-2-ylsulfamoyl)phenyl)-1-benzofuran-6-sulfonamide
-
50% inhibition of PTP1B at 0.008 mM, noncompetitive noncompetitive allosteric inhibitor, prevents formation of the active form of the enzyme by blocking the mobility of the catalytic loop
3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-sulfamoylphenyl)-1-benzofuran-6-sulfonamide
-
50% inhibition of PTP1B at 0.022 mM, noncompetitive allosteric inhibitor, prevents formation of the active form of the enzyme by blocking the mobility of the catalytic loop
3-(1-carboxy-ethoxy)-6-chloro-benzo(b)-thiophene-2-carboxylic acid
-
-
3-(2,2'-dimethyl-carboxypropanoyloxy)-oleanolic acid
-
-
3-(2,5-dimethyl-1H-pyrrol-1-yl)-4-hydroxybenzoic acid
-
20% residual activity at 0.1 mM; 3% residual activity at 0.1 mM; 52% residual activity at 0.1 mM; 7% residual activity at 0.1 mM
3-(2-carboxy-benzyloxy)-oleanolic acid
-
-
3-(2-carboxybenzoyloxy)-oleanolic acid
-
-
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethyl-1-benzofuran-6-sulfonamide
-
50% inhibition of PTP1B at 0.35 mM
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-(4-(thiazol-2-yl-sulfamyl)-phenyl)-amide
-
a PTP1b inhibitor, inhibit 50% tog the infectivity of Trypanosoma cruzi trypomastigotes
-
3-(3-carboxy-benzyloxy)-oleanolic acid
-
-
3-(4-carboxy-benzyloxy)-28-[4-butyric((s)-1-carboxyphenylethyl)-amide]-DELTA12-oleanene
-
-
3-(4-carboxy-benzyloxy)-oleanolic acid
-
-
3-(biphenyl-4-ylmethyl)-6-hydroxy-2-(4-hydroxybenzyl)-4H-chromen-4-one
P24666
-
3-(carboxy-fluoro-methoxy)-6-chloro-benzo(b)thiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-2-naphthoic acid
-
-
3-(carboxymethoxy)-5-((cyclohexylmethyl)-amino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-5-(cyclohexylamino)-thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-5-chlorothieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-((1-(ethylsulfonyl)-piperidin-4-yl)amino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-((cyclohexylmethyl)-amino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-(cyclohexylamino)-thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-(tetrahydro-2H-pyran-4-ylamino)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-chlorothieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)-6-methylthieno(3,2-c)pyridine-2-carboxylic acid
-
-
3-(carboxymethoxy)benzo(b)thiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)furo(2,3-b)pyridine-2-carboxylic acid
-
-
3-(carboxymethoxy)thieno(2,3-b)pyridine-2-carboxylic acid
-
reversible, competitive
3-(carboxymethoxy)thieno(3,2-b)(1)benzo-thiophene-2-carboxylic acid
-
-
3-(carboxymethoxy)thieno(3,2-b)pyridine-2-carboxylic acid
-
-
3-(carboxymethoxy)thieno(3,2-b)thiophene-2-carboxylic acid
-
-
3-benzyl-7-hydroxy-2-(4-hydroxybenzyl)-4H-chromen-4-one
P24666
10% inhibition of LMW-PTP isozymes 1 and 2,no inhibition of PTP-B1, at 0.015 mM
3-benzyloxy-oleanolic acid
-
-
3-butyl-7-(2,4-dihydroxy-6-pentylphenoxy)-3,5-dimethoxy-2-benzofuran-1(3H)-one
-
a pseudodepsidone-type compound, isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
3-carboxymethoxy-6-(4-hydroxyphenyl)-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-(5-methyl-1-phenyl-1H-pyrazol-3-ylcarbamoyl)-benzo(b)thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-chloro-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-phenylbenzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-6-thiophen-2-yl-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-7-chloro-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-7-methyl-benzo(b)-thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-naphtho(1,2-b)thiophene-2-carboxylic acid
-
-
3-carboxymethoxy-thieno(3,2-c)quinoline-2-carboxylic acid
-
-
3-carboxypropanoyloxy-oleanolic acid
-
-
3-chlorobenzenecarboperoxoic acid
-
complete inhibition at 150 mM
3-dehydroxy-oleanolic acid
-
-
3-ethyl oxalyl-oleanolic acid
-
-
3-hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl 3-acetyl-2,4-dihydroxy-6-methylbenzoate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
3-hydroxy-4-(methoxycarbonyl)-5-methylphenyl 4-(beta-D-galactopyranosyloxy)-2-hydroxy-6-pentadecylbenzoate
-
-
3-methyl-2-butenal
-
95% remaining activity at 0.5 mM
3-methylene-oleanolic acid
-
-
3-oxalyl-oleanolic acid
-
-
3-oxo-oleanolic acid
-
-
3-[(1-butyl-1,6-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-4-yl)oxy]-4,6-dihydroxy-2-pentylbenzoic acid
-
a pseudodepsidone-type compound, isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
3-[(2-nitrophenyl)hydrazono]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
-
-
3-[(2-nitrophenyl)hydrazono]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid 4-chlorobenzylamide
-
-
3-[(3-[(E)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
-
3-[(4-[(Z)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
-
3-[N'-(5-isopropylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidene)-hydrazino]benzoic acid
-
-
3-[oxalyl-amino]naphthalene-2-carboxylic acid
P18031
-
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4,6-dicarboxylic acid
-
25% residual activity at 0.1 mM; 39% residual activity at 0.1 mM; 65% residual activity at 0.1 mM; 73% residual activity at 0.1 mM
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4,8-dicarboxylic acid
-
30% residual activity at 0.1 mM; 53% residual activity at 0.1 mM; 63% residual activity at 0.1 mM; 79% residual activity at 0.1 mM
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
23% residual activity at 0.1 mM; 75% residual activity at 0.1 mM; 80% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
3alpha-oleanolic acid
-
-
3beta-acetoxy-17beta-hydroxy-28-norolean-12-ene
-
-
3beta-acetoxy-28-hydroxyolean-12-ene
-
-
3beta-acetoxyolean-12-en-28-acid
-
-
3beta-acetoxyolean-12-en-28-aldehyde
-
-
3beta-hydroxyolean-12-en-28-oic acid
-
-
4'-carboxy-3'-hydroxy-1,1'-biphenyl
P24666
no inhibition of LMW-PTP isozymes, but 10% inhibition of PTP-B1 at 0.02 mM
4'-[(2-butyl-1-benzofuran-3-yl)methyl]biphenyl-4-ol
P24666
-
4'-[2-(4-hydroxybutyl)-1-benzofuran-3-yl]biphenyl-4-ol
P24666
-
4,4'-[benzene-1,4-diylbis(methanediyloxy)]dibenzoic acid
-
-
4-((3E)-1-(1H-benzotriazol-1-yl)-1-(4-(difluoro(phosphono)methyl)benzyl)-4-phenylbut-3-en-1-yl)benzoic acid
-
50% inhibition at 39 nM for wild-type PTP-1B, at 39 nM for mutant V113I, at 45 nM for mutant M114V, at 29 nM for mutant V113I/M114V, at 32 nM for mutant G117E, at 142 nM for mutant L119V, and at 87 nM for isoform TCPTP wild-type and 24 nM for isoform TCPTP mutant V121L
4-((E)-2-nitrovinyl)benzoic acid
-
50% inhibition at 0.0027 mM in absence of 2-mercaptoethanol, at 0.425 mM in presence of 1 mM 2-mercaptoethanol
4-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
63% residual activity at 0.1 mM; 6% residual activity at 0.1 mM; 88% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-hydroxybenzoic acid
-
21% residual activity at 0.1 mM; 67% residual activity at 0.1 mM; 72% residual activity at 0.1 mM; 9% residual activity at 0.1 mM
4-(2,5-dimethyl-1H-pyrrol-1-yl)phthalic acid
-
18% residual activity at 0.1 mM; 54% residual activity at 0.1 mM; 78% residual activity at 0.1 mM; 80% residual activity at 0.1 mM
4-(beta-D-galactopyranosyloxy)-2-hydroxy-6-pentadecylbenzoic acid
-
-
4-(difluoro(phosphono)methyl)-N-pentadecanoyl-L-phenylalanyl-L-a-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
-
4-(difluoro(phosphono)methyl)-N-pentadecanoyl-L-phenylalanyl-L-alpha-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
dose-dependent increase in Y527 phosphorylation of Src
4-([(5E)-5-[3-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
-
4-([(5Z)-5-[4-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
-
4-chloro-N-(6-ethoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-chloro-N-(6-methoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-chloro-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-fluoro-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-isoavenaciolide
P30304, P30305, P30307
potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR
4-methoxy-3-(5-methoxy-1-benzofuran-6-yl)-5-(4-methoxyphenyl)isoxazole
P30304, P30305, P30307
-
4-methoxy-3-(5-methoxy-1-benzofuran-6-yl)-5-phenylisoxazole
P30304, P30305, P30307
-
4-methoxy-N-(6-methoxy-1,3-benzothiazol -2-yl)benzenesulfonamide
-
-
4-methoxy-N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-methoxy-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-methyl-N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-methyl-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-nitro-N-(6-nitro-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
4-nitrocatechol sulfate
-
applied from from bare and amine functionalized mesoporous silica, MCM-48, and mesoporous alumina for sustained delivery, competitive inhibition, kinetics, overview
4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.073 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-6,8-diphenyl-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0033 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
4-oxo-6-(2-phenyl-1-benzothien-3-yl)-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0062 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-6-phenyl-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.014 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-8-(phenylsulfanyl)-1,4-dihydro-1,7-naphthyridine-3-carboxylic acid
-
-
4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.016 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-[(1E)-3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl]-5-methoxy-2-(2-methylbut-3-en-2-yl)phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(2,4-dihydroxy-6-pentadecylbenzoyl)oxy]-2-hydroxy-6-methylbenzoic acid
-
-
4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl 4-bromobenzoate
-
-
4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl 4-tert-butylbenzoate
-
-
4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl benzoate
-
-
4-[(2E)-3-[2,4-dimethoxy-5-(2-methylbut-3-en-2-yl)phenyl]prop-2-enoyl]phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(2E)-3-[4-(acetyloxy)-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]prop-2-enoyl]phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]prop-2-enoyl]phenyl acetate
-
a semisynthetic licochalcone A derivative
4-[(3-[(E)-[(2Z)-3-(4-carboxybenzyl)-4-oxo-2-(phenylimino)-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
-
4-[(3-[(E)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
-
4-[(4-[(Z)-[(2Z)-3-(4-carboxybenzyl)-4-oxo-2-(phenylimino)-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
-
4-[(4-[(Z)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
-
4-[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]butanoic acid
-
-
4-[difluoro(phosphono)methyl]benzoic acid
-
-
4-[N'-(5-isopropylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidene)-hydrazino]benzoic acid
-
-
4-[[(2Z,5E)-5-(3-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
-
4-[[(2Z,5E)-5-[3-(benzyloxy)benzylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
-
4-[[(2Z,5Z)-5-(4-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
-
4-[[(2Z,5Z)-5-[4-(benzyloxy)benzylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
-
4-[[(5E)-5-(3-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
-
4-[[(5Z)-5-(4-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
-
5-(2-fluoro-5-((1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]prop-1-en-1-yl)phenyl)isoxazole-3-carboxylic acid
P30304, P30305, P30307
-
5-acetylamino-2-(2,5-dimethyl-1H-pyrrol-1-yl) benzoic acid
-
45% residual activity at 0.1 mM; 46% residual activity at 0.1 mM; 82% residual activity at 0.1 mM; 94% residual activity at 0.1 mM
5-methoxy-4-[(1E)-3-(4-methoxyphenyl)-3-oxoprop-1-en-1-yl]-2-(2-methylbut-3-en-2-yl)phenyl acetate
-
a semisynthetic licochalcone A derivative
6,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(1,1-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
6,8-dibenzyl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.013 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-((1-(benzylsulfonyl)piperidin-4-yl)amino)-3-(carboxymethoxy)thieno(3,2-b)(1)benzothiophene-2-carboxylic acid
-
-
6-((2-benzyl-1-benzothien-3-yl)methyl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0032 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-((E)-1,2-diphenylvinyl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0097 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-2-ylmethyl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.006 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-3-yl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0077 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-3-ylmethyl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.06 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(10-bromo-9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0025 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR at 0.57 mM
6-(4-((2-benzyl-1-benzothiophen-3-yl)methyl)phenyl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-(4-((2-benzyl-1-benzothiophen-3-yl)methyl)phenyl)-4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.001 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR at 0.52 mM
6-(9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0071 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-benzyl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.036 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-biphenyl-4-yl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0043 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-biphenyl-4-yl-4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.002 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-bromo-3-carboxymethoxy-benzo(b)-thiophene-2-carboxylic acid
-
-
6-bromo-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.020 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-chloro-7-(2,3-dihydro-1H-inden-1-ylamino)quinoline-5,8-dione
-
-
6-chloro-7-[(2-morpholin-4-ylethyl)amino]quinoline-5,8-dione
-
-
6-dibenzo(b,d)thien-1-yl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0076 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-dibenzo(b,d)thien-4-yl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-fluoro-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
35% residual activity at 0.1 mM; 63% residual activity at 0.1 mM; 72% residual activity at 0.1 mM; 75% residual activity at 0.1 mM
6-hydroxy-2-(4-hydroxybenzyl)-3-[(1,1-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
; 20% inhibition of PTP-B1 at 0.015 mM
6-hydroxy-3-[1-[4-(naphthalen-1-ylamino)-4-oxobutyl]-1H-1,2,3-triazol-4-yl]-2-phenyl-1-benzofuran-5-carboxylic acid
-
-
6-hydroxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylate
-
80% residual activity at 0.1 mM
6-hydroxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
38% residual activity at 0.1 mM; 50% residual activity at 0.1 mM; 73% residual activity at 0.1 mM
7-bromo-6-difluoromethylphosphonate 3-naphthalenenitrile
P18031
50% inhibiton at 230 nM for wild-type, at 886 nM for mutant S295F
7-chloro-6-[(2-morpholin-4-ylethyl)amino]quinoline-5,8-dione
-
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(3'',4''-dihydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(3''-carboxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(4''-carboxy-3''-hydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
7-hydroxy-2-(4'-hydroxyphenyl)-3-[(4''-hydroxy-1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
-
7-hydroxy-2-(4-hydroxybenzyl)-4H-chromen-4-one
P24666
10% inhibition of LMW-PTP isozymes 1 and 2,no inhibition of PTP-B1, at 0.015 mM
7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one
-
isolated from the CH2Cl2 extract of Glycyrrhiza inflata
7-hydroxy-2-(4-hydroxyphenyl)-3-[(3',4'-dihydroxy-1,1-biphenyl-3-yl)methyl]-4H-1-benzopyran-4-one
P24666
60% inhibition of LMW-PTP isozyme 2, 25% inhibition of LMW-PTP 1, and 50% inhibition of PTP-B1, at 0.02 mM
7-hydroxy-2-(4-hydroxyphenyl)-3-[(4'-carboxy-3'-hydroxy-1,1-biphenyl-3-yl)methyl]-4H-1-benzopyran-4-one
P24666
5% inhibition of LMW-PTP isozyme 2, 10% inhibition of LMW-PTP 1, and 59% inhibition of PTP-B1, at 0.02 mM
7-hydroxy-2-(4-hydroxyphenylethyl)-3-[(1,1-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
; 20% inhibition of PTP-B1 at 0.015 mM
7-hydroxy-2-(4-hydroxyphenylmethyl)-3-[(1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
; 10% inhibition of PTP-B1 at 0.015 mM
7-hydroxy-2-(4-hydroxyphenylpropyl)-3-[(1,1'-biphenyl-4-yl)methyl]-4H-1-benzopyran-4-one
P24666
10% inhibition of LMW-PTP isozymes 1 and 2,no inhibition of PTP-B1, at 0.015 mM
8-acetyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
48% residual activity at 0.1 mM; 66% residual activity at 0.1 mM; 81% residual activity at 0.1 mM; 83% residual activity at 0.1 mM
8-benzyl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.018 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid
-
33% residual activity at 0.1 mM; 41% residual activity at 0.1 mM; 8% residual activity at 0.1 mM; 90% residual activity at 0.1 mM
8-bromo-4-oxo-6-(2-phenyl-1-benzothien-3-yl)-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0078 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-(10-bromo-9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-(2-bromo-1-benzothien-3-yl)-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.0082 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-dibenzo(b,d)thien-1-yl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.010 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-dibenzo(b,d)thien-4-yl-4-oxo-4H-chromene-3-carbaldehyde
-
50% inhibition at 0.016 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-hydroxy-3-methoxy-11-oxo-1-pentanoyl-6-pentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylic acid
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
acanthoic acid
-
diterpenoid isolated from Acanthopanax koreanum, 50% inhibition at 0.024 mM
acetaldehyde
-
more than 95% remaining activity at 0.5 mM
acid
-
-
-
acrolein
-
4% remaining activity at 0.5 mM, potent irreversible time-dependent inhibitor, addition of 1 mM vanadate slows inactivation of PTP1B by 0.5 mM acrolein
Ag+
-
16.6% inhibition at 2 mM
Ammonium molybdate
-
complete inhibition of enzyme isolated from metacyclic stage, 75% inhibition of enzyme from procyclic stage
Ammonium molybdate
-
4% residual activity in ovary and no activity in haemolymph at 1 mM
Ammonium molybdate
-
strong inhibition
antimonate
-
inhibition of protein tyrosine phosphatase activity
aquastatin A
-
derived from marine fungus Cosmospora sp. SF-5060, competitive inhibition
arsenate
-
inhibition of protein tyrosine phosphatase activity
auranofin
Homo sapiens, Yersinia enterolytica
-
inhibition of cysteine-dependent protein tyrosine phosphatases
benzenesulfonamide
-
-
benzyl (3R,6S)-4,9-dioxo-3-[(R)-phenyl(phenylamino)methyl]-1,5-diazonane-6-carboxylate
-
-
benzyl oleanolic acid amide
-
-
benzyl oleanolic acid ester
-
-
Berberine
-
binding structure, molecular modeling, overview
betulinic acid
-
95.1% PTP1B inhibitory activity with 0.0007 mg/ml
betulinic acid methyl ester
-
89.4% PTP1B inhibitory activity with 0.00093 mg/ml
biphenyl-3,4-diol
P24666
25% inhibition of LMW-PTP isozyme 2, and 10% inhibition of LMW-PTP 1 and PTP-B1 at 0.02 mM
BzN-EJJ-amide
P18031
50% inhibiton at 3.7 nM for wild-type, at 18 nM for mutant S295F
BzN-EJJ-amide
-
50% inhibition at 8nM for wild-type PTP-1B, at 14 nM for PTP-1B mutant V113I, at 7 nM for mutant M114V, at 7 nM for mutant V113I/M114V, at 11 nM for mutant G117E, at 12 nM for mutant L119V
calopocarpin
-
-
chloro(1,3-dimethyl-2,3-dihydro-1H-imidazol-2-yl)gold
-
i.e. [(p-MeMeIm)AuICl]
chloro(1-methyl-2,3-dihydro-1H-imidazol-2-yl)gold
-
i.e. [(MeIm)AuICl]
chloro[1-methyl-3-(4-methylbenzyl)-2,3-dihydro-1H-imidazol-2-yl]gold
-
i.e. [(p-MeBzMeIm)AuICl]
CinnGel 2ME
-
30.2% inhibition at 0.02 mM
CinnGel 2ME
-
the free cinnamic acid component of CinnGEL 2Me inhibits PTP1B
corosolic acid
-
50% inhibition at 0.0072mM, mixed-type inhibition
Cr(VI)
-
as Na2CrO4, induces clonogenic lethality
crotonaldehyde
-
85% remaining activity at 0.5 mM
Cu2+
-
32.2% inhibition at 2 mM
Cu2+
-
lung enzyme
dehydrocostuslactone
-
86.2% PTP1B inhibitory activity with 0.00651 mg/ml
dephostatin
-
complete inhibition of enzyme isolated from metacyclic stage, 28% inhibition of enzyme from procyclic stage
Differentiation inducing factor 1
-
DIF-1, inhibits PTP3 by induction of serine-threonine phosphorylation of PTP3
-
diphosphate
-
1 mM, 31% residual activity
diphosphate
-
-
diphosphate
-
-
diphosphate
-
-
disodium 3-(((4-methyl-3-(((2-methyl-5-((3-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)benzenesulfonate
-
suramin-derivative, 50% inhibition at 0.030 mM, reversible and competitive
disodium 4-(((4-methyl-3-(((3-(((3-((2-methyl-5-((4-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)benzenesulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.010 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
disodium 4-(((4-methyl-3-(((3-(((3-((2-methyl-5-((4-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)benzenesulfonate
-
suramin-derivative, 50% inhibition at 0.012mM, reversible and competitive
disodium hydrogen (3-(((4-(((4-((3-(hydroxyphosphinato)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)phosphonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.0096 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
disodium hydrogen (3-(((4-(((4-((3-(hydroxyphosphinato)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)phosphonate
-
suramin-derivative, 50% inhibition above 0.1 mM, reversible and competitive
DTT
-
inhibition of cytosolic enzyme form
dysidiolide
P30304, P30305, P30307
inhibits Cdc25A
ent-kaur-16-en-19-oic acid
-
diterpenoid isolated from Acanthopanax koreanum, 50% inhibition at 0.020 mM
erybraedin A
-
-
erylysins A
-
i.e. 3''-hydroxy-2',2'-dimethylpyrano[6',5':3,4]-2'',2''-dimethyldihydropyrano[6'',5'':9,10]pterocarpan, a pterocarpan isolated from stem bark of Erythrina lysistemon, inhibits PTPB1
erylysins B
-
i.e. furano[5',4':3,4]-9-hydroxy-10-prenylpterocarpan, a pterocarpan isolated from stem bark of Erythrina lysistemon, inhibits PTPB1
erysubin D
-
-
eryvarin D
-
-
ethyl 4-[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]butanoate
-
-
ethyl [4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]acetate
-
-
ethyl-3,4-dephostatin
P30304, P30305, P30307
-
Fe2+
-
34.5% inhibition at 2 mM
Fe2+
-
lung enzyme
FlAsH
-
the small molecule biarsenical fluorescein derivative, FlAsH, is no inhibitor of the wild-type enzyme but of the engineered WPD insertion mutant enzyme that displays FlAsH-binding cysteine residues. Inhibition of the FlAsH-sensitized TCPTP mutants is rapid and specific, and strong FlAsH sensitivity is observed in mutants that contain as few as two cysteine point mutations in their engineered WPD loops, minimization of FlAsH-binding determinants, overview
fluorescein arsenical hairpin binder
-
fluorescein arsenical hairpin binder does not inhibit any wild type PTP, but insertion of a fluorescein arsenical hairpin binder-binding peptide (CCPGCC) at a conserved position in the PTP catalytic-domain's WPD loop confers fluorescein arsenical hairpin binder sensitivity upon divergent PTPs
-
formaldehyde
-
-
glycyrrhetic acid
-
-
Glyoxal
-
93% remaining activity at 0.5 mM
glyoxalbis(N(4)-methylthiosemicarbazonato)Cu(II)
-
inhibition of protein tyrosine phosphatase activity is the prerequisite for activation of epidermal growth factor receptor by the compound, overview
H2O2
-
inactivation, phosphate protects, mechanism, overview
H3VO4
-
no effect on PTP-I but PTP-III inhibited
H3VO4
-
slight effect
heparin
-
-
hexadecanoyl-5-hydroxymethyl tetronic acid
P30304, P30305, P30307
potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR; potent irreversible inhibitor of VHR
hexasodium 8,8'-(((2E)-1,4-dioxobut-2-ene-1,4-diyl)bis(iminobenzene-3,1-diylcarbonylimino(4-methylbenzene-3,1-diyl)carbonylimino))dinaphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.005 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8,8'-(((2E)-1,4-dioxobut-2-ene-1,4-diyl)bis(iminobenzene-3,1-diylcarbonylimino(4-methylbenzene-3,1-diyl)carbonylimino))dinaphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.008mM, reversible and competitive
hexasodium 8,8'-(benzene-1,3-diylbis(carbonyliminobenzene-3,1-diylcarbonylimino(4-methylbenzene-3,1-diyl)carbonylimino))dinaphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.0023 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8,8'-(benzene-1,3-diylbis(carbonyliminobenzene-3,1-diylcarbonylimino(4-methylbenzene-3,1-diyl)carbonylimino))dinaphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.0015M, reversible and competitive
hexasodium 8-(((2'-(((3'-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)biphenyl-2-yl)carbamoyl)amino)biphenyl-4-yl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.070 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-(((2'-(((3'-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)biphenyl-2-yl)carbamoyl)amino)biphenyl-4-yl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.020 mM, reversible and competitive
hexasodium 8-(((3-methyl-4-(((3-(((3-((2-methyl-4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.0037 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-(((3-methyl-4-(((3-(((3-((2-methyl-4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.007 mM, reversible and competitive
hexasodium 8-(((3-methyl-4-(((4-(((4-((4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.0021 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-(((3-methyl-4-(((4-(((4-((4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.0028mM, reversible and competitive
hexasodium 8-(((4-(((3-(((3-((4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.0016 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-(((4-(((3-(((3-((4-((4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.002mM, reversible and competitive
hexasodium 8-(((4-(1-methylethyl)-3-(((3-(((3-((2-(1-methylethyl)-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.009 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-(((4-(1-methylethyl)-3-(((3-(((3-((2-(1-methylethyl)-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.013M, reversible and competitive
hexasodium 8-(((4-ethyl-3-(((3-(((3-((2-ethyl-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.009 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-(((4-ethyl-3-(((3-(((3-((2-ethyl-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.011M, reversible and competitive
hexasodium 8-(((4-tert-butyl-3-(((3-(((3-((2-tert-butyl-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.007 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-(((4-tert-butyl-3-(((3-(((3-((2-tert-butyl-5-((4,5,8-trisulfonatonaphthalen-1-yl)carbamoyl)phenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)phenyl)carbonyl)amino)naphthalene-1,4,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.013M, reversible and competitive
hexasodium 8-([[2-(3-[[(3-[5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]-1H-benzimidazol-2-yl]phenyl)carbamoyl]amino]phenyl)-1H-benzimidazol-5-yl]carbonyl]amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.00049 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
hexasodium 8-([[2-(3-[[(3-[5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]-1H-benzimidazol-2-yl]phenyl)carbamoyl]amino]phenyl)-1H-benzimidazol-5-yl]carbonyl]amino)naphthalene-1,3,5-trisulfonate
-
suramin-derivative, 50% inhibition at 0.00009M, reversible and competitive
iodoacetic acid
-
-
iodoacetic acid
-
-
iodoacetic acid
Q64604
-
ISIS 113715
-
PTP-1B antisense oligonucleotide ISIS 113715 dose-dependently inhibits PTP-1B mRNA and protein expression, although ISIS 113715 reduces PTP-1B protein levels by greater than 90%, no effects are observed on protein levels of TC-PTPase
-
ISIS 113715
-
PTP-1B antisense oligonucleotide ISIS 113715 administration reduces PTP-1B mRNA expression in both liver and adipose tissue by 40-50% but does not affect muscle PTP-1B expression
-
isoneorautenol
-
-
JTT-551
-
i.e. monosodium (([5-(1,1-dimethylethyl)thiazol-2-yl]methyl)([(4-(4-[4-(1-propylbutyl)phenoxy]methyl)phenyl)thiazol-2-yl]methyl)amino)acetate, a specific protein tyrosine phosphatase 1B inhibitor in vitro and in vivo, mixed-type inhibition mode versus PTPB1, overview
JTT-551
-
i.e. monosodium (([5-(1,1-dimethylethyl)thiazol-2-yl]methyl)([(4-(4-[4-(1-propylbutyl)phenoxy]methyl)phenyl)thiazol-2-yl]methyl)amino)acetate, a specific protein tyrosine phosphatase 1B inhibitor in vitro and in vivo, mixed-type inhibition mode versus PTPB1, overview. The inhibitor shows a hypoglycaemic effect in ob/ob mice, overview
JTT-551
-
i.e. monosodium (([5-(1,1-dimethylethyl)thiazol-2-yl]methyl) ([(4-(4-[4-(1-propylbutyl)phenoxy]methyl)phenyl)thiazol-2-yl]methyl)amino)acetate, a specific protein tyrosine phosphatase 1B inhibitor in vitro and in vivo, mixed-type inhibition mode versus PTPB1, overview. The inhibitor shows a hypoglycaemic effect in rat L6 cells, overview
kanjone
P30304, P30305, P30307
-
karanjin
P30304, P30305, P30307
-
L-phenylalanine
-
-
L-Tartrate
-
weak
L-Tartrate
-
no inhibition of platelet enzyme
L-Tartrate
-
no inhibition of lung enzyme
lobaric acid
-
a depsidone-type compound, isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
lupenone
-
isolated from Sorbus commixta stem bark, inhibits PTP1B in a selective and noncompetitive manner
lupeol
-
isolated from Sorbus commixta stem bark, inhibits PTP1B in a selective and noncompetitive manner
maslinic acid
-
poor inhibition by the isomers 3-epi-maslinic acid and augustic acid
menadione
P30304, P30305, P30307
inhibits Cdc25B irreversibly
methyl (6S,10S)-12-(2-chloro-3-hydroxybenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-(2-fluoro-5-iodobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-(2-hydroxybenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-(3,4-dichlorobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
; absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-(3,4-difluorobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-(3-bromo-4-fluorobenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-(3-hydroxybenzyl)-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
; absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-benzyl-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-12-[(4,6-dichloro-2H-chromen-3-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-[(4-chloro-6-fluoro-2H-chromen-3-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA, inhibition kinetics, overview
methyl (6S,10S)-12-[(5-chloro-1H-indol-3-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-12-[(5-methylfuran-2-yl)methyl]-9-oxo-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
absolutely specific for MptpB, no inhibition of MptpA
methyl (6S,10S)-9-hydroxy-12-(3-hydroxybenzyl)-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl (6S,10S)-9-oxo-12-(pyridin-3-ylmethyl)-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]indole-8-carboxylate
-
-
methyl 2,4-dihydroxy-6-methylbenzoate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl 2-[4-[(4-[[ethoxy(oxo)acetyl][2-(methoxycarbonyl)phenyl]amino]-3-ethylphenylalanyl)amino]butoxy]-6-hydroxybenzoate
P30304, P30305, P30307
-
methyl 3,8-dimethoxy-11-oxo-1-pentanoyl-6-pentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl 3-formyl-2,4-dihydroxy-6-methylbenzoate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl 4-[(benzylseleninyl)methyl]-N-(tert-butoxycarbonyl)-L-phenylalaninate
-
-
methyl 5-amino-6-(7-amino-6-methoxy-5,8-dioxo-5,8-dihydroquinolin-2-yl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpyridine-2-carboxylate
-
-
methyl 8-hydroxy-3-methoxy-11-oxo-1-pentanoyl-6-pentyl-11H-dibenzo[b,e][1,4]dioxepine-7-carboxylate
-
isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum
methyl N-(tert-butoxycarbonyl)-4-(hydroxymethyl)-L-phenylalaninate
-
-
methyl N-(tert-butoxycarbonyl)-4-[(5R)-5-(methoxycarbonyl)-9,9-dimethyl-7-oxo-8-oxa-3-thia-2-selena-6-azadec-1-yl]-L-phenylalaninate
-
-
methyl oleanolic acid amide
-
-
methyl oleanolic acid ester
-
-
Mn2+
-
no inhibition of platelet enzyme
mokko lactone
-
93.1% PTP1B inhibitory activity with 0.00141 mg/ml
molybdate
-
92.2% inhibition at 5 mM
molybdate
-
no effect on PTP-I, PTP-III inhibited
molybdate
Q64604
-
mpV(pic)
-
potent and selective PTP inhibitor, inhibits SPH-1 in a dose-dependent manner
N,N'-[benzene-1,4-diylbis(propane-2,2-diylbenzene-4,1-diyl)]bis(1,1,1-trifluoromethanesulfonamide)
-
-
N-((4-((E)-2-nitroethenyl)phenyl)carbonyl)glycyl-L-alpha-glutamyl-L-glutamic acid
-
50% inhibition at 0.0014 mM in absence of 2-mercaptoethanol, at 0.275 mM in presence of 1 mM 2-mercaptoethanol
N-((4-(difluoro(phosphono)methyl)phenyl)acetyl)-L-a-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
inhibition of enzyme increases caveolin-1 phosphorylation
N-((4-(difluoro(phosphono)methyl)phenyl)acetyl)-L-alpha-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalaninamide
-
-
N-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-(4-methylphenyl)acetamide
-
-
N-(3-formylphenyl)-3-(((3-((3-formylphenyl)carbamoyl)phenyl)carbamoyl)amino)benzamide
-
suramin-derivative, 50% inhibition of PTP1B above 0.1 mM, reversible and competitive. Not inhibitory to PTPalpha, CD45 or LAR
N-(3-formylphenyl)-3-(((3-((3-formylphenyl)carbamoyl)phenyl)carbamoyl)amino)benzamide
-
suramin-derivative, 50% inhibition above 0.1 mM, reversible and competitive
N-(3-[(4-chlorophenyl)sulfanyl]-1,4-dioxo-1,4-dihydronaphthalen-2-yl)acetamide
-
-
N-(4-([(6-ethoxy-1,3-benzothiazol-2-yl)amino]sulfonyl)phenyl)acetamide
-
-
N-(4-([(6-methoxy-1,3-benzothiazol-2-yl)amino]sulfonyl)phenyl)acetamide
-
-
N-(4-([(6-methyl-1,3-benzothiazol-2-yl)amino]sulfonyl)phenyl)acetamide
-
-
N-(4-[[(6-nitro-1,3-benzothiazol-2-yl)amino]sulfonyl]-phenyl)acetamide
-
-
N-(6-chloro-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)-4-methoxybenzenesulfonamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)-4-methylbenzenesulfonamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)-4-nitrobenzene sulfonamide
-
linear mixed-type inhibition, shows in vivo antihyperglycemic activity
N-(6-ethoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
N-(6-fluoro-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
-
N-(6-methoxy-1,3-benzothiazol-2-yl)-4-methylbenzenesulfonamide
-
-
N-(6-methoxy-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
-
N-(6-methoxy-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
N-(6-methyl-1,3-benzothiazol-2-yl)-4-nitrobenzenesulfonamide
-
linear mixed-type inhibition, shows in vivo antihyperglycemic activity
N-(6-methyl-1,3-benzothiazol-2-yl)benzenesulfonamide
-
-
N-([4-[difluoro(phosphono)methyl]phenyl]acetyl)-a-aspartyl-4-[difluoro(phosphono)methyl]phenylalaninamide
-
-
N-benzoyl-L-glutamyl-[4-phosphono(difluoromethyl)]-L-phenylalanineamide
-
i.e. BzN-EJJ-amide, 50% inhibition at 4 nM
n-dodecyl trimethylammonium bromide
-
pH 7.0, inactivation at concentration 10fold higher than critical micellar concentration
N-ethylmaleimide
-
both isozymes, 50% inhibition at 7 mM
N-ethylmaleimide
-
-
N-ethylmaleimide
Q64604
-
n-hexadecyl trimethylammonium bromide
-
pH 7.0, inactivation at concentration 10fold higher than critical micellar concentration
N-Methylmaleimide
-
76.3% inhibition at 0.5 mM
n-tetradecyl trimethylammonium bromide
-
pH 7.0, inactivation at concentration 10fold higher than critical micellar concentration
N-[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenyl]-4-tert-butylbenzamide
-
-
N-[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-N-methyl-2-(4-nitrophenyl)ethanaminium
-
-
N2-(2-((2-((N-((4-(difluoro(phosphono)methyl)phenyl)acetyl)-L-alpha-aspartyl-4-(difluoro(phosphono)methyl)-L-phenylalanyl)amino)ethyl)disulfanyl)ethyl)-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-argininamide
-
in presence of 5-50 nM, 11-35% decrease in cell spreading, 24% decrease in number of migratory cells, dose-dependent increase in Y527 phosphorylation of Src
Na+/K+ tartrate
-
20% residual activity in ovary and 2% residual activity in haemolymph at 10 mM
NaCl
-
increase in Km-value with increase of ionic strength, 10-fold increase of Km-value from 0 to 200 mM NaCl
NaCl
-
inhibits activity with 4-nitrophenyl phosphate
NaF
-
1 mM, 85% residual activity
NaF
-
moderate inhibition, both SynPPP1 and SYnPPM3
NaF
-
16% residual activity in ovary and no activity in haemolymph at 10 mM
NaF
-
no inhibition of platelet enzyme
NaF
-
no inhibition of lung enzyme
NaF
Q06124
slight inhibition
NAT6-297775
-
-
NO
-
inactivation, phosphate protects
nocardione A
P30304, P30305, P30307
inhibits Cdc25B
nocardione B
P30304, P30305, P30307
inhibits Cdc25B
NSC-87877
-
potent Shp2 and Shp1 inhibitor
o-vanadate
-
both SynPPP1 and SYnPPM3
okadaic acid
-
both SynPPP1 and SYnPPM3
okadaic acid
-
complete inhibition of enzyme isolated from metacyclic stage, 35% inhibition of enzyme from procyclic stage
oleanolic acid
-
-
oleanolic acid amide
-
-
oleanolic alcohol
-
-
oleanonic acid
-
-
orientanol C
-
-
orthovanadate
Q6JHV2
50% inhibition at 0.075 mM
orthovanadate
-
inhibition of protein tyrosine phosphatase activity
orthovanadate
-
24.5% inhibition at 5 mM
orthovanadate
-
-
p-chloromercuribenzoate
-
lung enzyme
p-hydroxymercuribenzoate
Q64604
-
p-nitrocatechol sulfate
-
competitive inhibitor
papaverine
-
binding structure, molecular modeling, overview
peracetic acid
-
a potent, time-dependent inactivator of the catalytic subunit of PTP1B, treatment of the enzyme with 0.015 mM for 15 sec inactivates 88% of the enzyme, inactivation of PTP1B by peracetic acid can be reversed by treatment of the enzyme with thiols
pervanadate
-
pervanadate inhibits PTP by irreversibly oxidizing the catalytic cysteine of PTP
-
pervanadate
-
-
-
phaseollin
-
-
phenyl vinyl sulfonate
-
phenyl vinyl sulfonate-mediated PTP inactivation is active site-directed and irreversible
phenyl vinyl sulfone
-
phenyl vinyl sulfone-mediated PTP inactivation is active site-directed and irreversible
Phenylarsine oxide
-
55.8% inhibition at 0.01 mM
Phenylarsine oxide
-
specific inhibitor of protein Tyr phosphatase activity
Phenylarsine oxide
-
-
Phenylarsine oxide
Q06124
-
phenylhydrazonopyrazolone sulfonate 1
-
potent, active site-directed small molecule inhibitor which is specific for Shp2 over the closely related tyrosine phosphatases Shp1 and PTP1B
phenylhydrazonopyrazolone sulfonate 4
-
the most potent inhibitor of Shp2 which shows a specificity profile similar to phenylhydrazonopyrazolone sulfonate 1
phosphate
-
competitive
phosphate
-
38% residual activity in ovary and 3% residual activity in haemolymph at 10 mM
phosphate
-
-
phosphotyrosine
-
-
phosphotyrosine
-
-
PO43-
-
treatment of the enzyme with 0.05 mM PO43- for 15 sec inactivates 49% of the enzyme
pomolic acid
-
-
potassium bisperoxo(1,10-phenanthroline)oxovanadate
-
-
potassium bisperoxo(1,10-phenanthroline)oxovanadate
-
complete inhibition at 0.01 mM
potassium bisperoxo(1,10-phenanthroline)oxovanadate
-
potent PTP inhibitor
potassium bisperoxo(1,10-phenanthroline)oxovanadate(V)
-
i.e. [bpV(phen)], the peroxovanadium compound is a stable, potent and selective protein tyrosine phosphatase inhibitor. It protects dorsal column sensory axons and white matter and rescues sensory-evoked potentials in vivo after treatement with PTP or spinal cord injury, overview
propanal
-
93% remaining activity at 0.5 mM
regucalcin
-
regulatory protein in intracellular signaling
-
RK-682
-
98.5% PTP1B inhibitory activity with 0.0012 mg/ml
rotungenic acid
-
-
small t antigen
-
small t antigen of DNA tumor virus SV40 inhibits the phosphatase activity of the PP2A core enzyme
-
sodium decylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
Sodium diphosphate
-
both isoforms, inhibition by millimolar concentrations
sodium dodecylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
sodium octylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
sodium orthovanadate
-
-
sodium orthovanadate
-
both isozymes, 50% inhibition at 3 mM
sodium orthovanadate
-
complete inhibition of enzyme isolated from metacyclic stage, 30% inhibition of enzyme from procyclic stage
sodium orthovanadate
-
20% residual activity in ovary and 13% residual activity in haemolymph at 0.1 mM
sodium orthovanadate
-
shows dose-dependent inhibition of PRL activity
sodium orthovanadate
-
17.5% inhibition at 1 mM
sodium orthovanadate
-
a broad-range PTP inhibitor, abrogated Cr(VI)-induced clonogenic lethality
sodium orthovanadate
-
strong inhibition
sodium pervanadate
-
broad-acting tyrosine phosphatase inhibitor
Sodium tetradecylsulfate
-
at concentration 10fold lower than critical micellar concentration, complete inactivation. Inactivation is independent of pH-value, irreversible and not affected by NaCl. Presence of phosphate protects
sodium tungstate
-
complete inhibition of enzyme isolated from metacyclic stage, 50% inhibition of enzyme from procyclic stage
Sodium vanadate
-
1 mM, 60-80% inhibition
Sodium vanadate
P30304, P30305, P30307
-
spathodic acid
-
-
spermidine
-
-
spermine
-
2.0-20 mM
stevastelin
P30304, P30305, P30307
inhibits VHR; inhibits VHR; inhibits VHR
stigmasterol
-
-
sulfircin
P30304, P30305, P30307
inhibits Cdc25A
suramin
-
50% inhibition of PTP1B at 0.011 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
suramin
-
50% inhibition at 0.007M, reversible and competitive
taraxerol
-
-
Tartrate
-
both SynPPP1 and SYnPPM3
tetramisole
-
both SynPPP1 and SYnPPM3
tetrasodium 2-(((2-(3-(((3-(5-((2,5-disulfonatophenyl)carbamoyl)-1H-benzimidazol-2-yl)phenyl)carbamoyl)amino)phenyl)-1H-benzimidazol-5-yl)carbonyl)amino)benzene-1,4-disulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.00025 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
tetrasodium 2-(((2-(3-(((3-(5-((2,5-disulfonatophenyl)carbamoyl)-1H-benzimidazol-2-yl)phenyl)carbamoyl)amino)phenyl)-1H-benzimidazol-5-yl)carbonyl)amino)benzene-1,4-disulfonate
-
suramin-derivative, 50% inhibition at 0.0007mM, reversible and competitive
tetrasodium 4,4'-(benzene-1,3-diylbis(carbonylimino))dinaphthalene-2,6-disulfonate
-
suramin-derivative, 50% inhibition of PTP1B above 0.1 mM, reversible and competitive. Not inhibitory to PTPalpha, CD45 or LAR
tetrasodium 4,4'-(benzene-1,3-diylbis(carbonylimino))dinaphthalene-2,6-disulfonate
-
suramin-derivative, 50% inhibition above 0.1 mM, reversible and competitive
tetrasodium 4,4'-(benzene-1,3-diylbis(carbonyliminobenzene-4,1-diylcarbonylimino))dinaphthalene-2,6-disulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.08 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
tetrasodium 4,4'-(benzene-1,3-diylbis(carbonyliminobenzene-4,1-diylcarbonylimino))dinaphthalene-2,6-disulfonate
-
suramin-derivative, 50% inhibition at 0.045 mM, reversible and competitive
tetrasodium 4-(((3-(((3,5-bis((4-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)amino)-5-((4-sulfonatophenyl)carbamoyl)phenyl)carbonyl)amino)benzenesulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.0045 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
tetrasodium 4-(((3-(((3,5-bis((4-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)amino)-5-((4-sulfonatophenyl)carbamoyl)phenyl)carbonyl)amino)benzenesulfonate
-
suramin-derivative, 50% inhibition at 0.005mM, reversible and competitive
tetrasodium 4-(((3-(((5-((4,8-disulfonatonaphthalen-1-yl)carbamoyl)-2-methylphenyl)carbamoyl)amino)-4-methylphenyl)carbonyl)amino)naphthalene-1,5-disulfonate
-
suramin-derivative, 50% inhibition of PTP1B at 0.070 mM, reversible and competitive. Not inhibitory to PTPalpha or LAR
tetrasodium 4-(((3-(((5-((4,8-disulfonatonaphthalen-1-yl)carbamoyl)-2-methylphenyl)carbamoyl)amino)-4-methylphenyl)carbonyl)amino)naphthalene-1,5-disulfonate
-
suramin-derivative, 50% inhibition at 0.0042 mM, reversible and competitive
Trifluoperazine
-
complete inhibition of enzyme isolated from metacyclic stage, 18% inhibition of enzyme from procyclic stage
tungstate
-
16.3% inhibition at 20 mM
tungstate
-
-
ursolic acid
-
50% inhibition at 0.0038 mM, competitive inhibition
ursolic acid
-
99% PTP1B inhibitory activity with 0.0007 mg/ml
vanadate
-
competitive, 1 mM, 11% residual activity
vanadate
-
enzyme inhibition by vanadate takes place through an oxidant-independent pathway, the inhibition is reversible with EDTA
vanadate
-
the equatorial vanadate oxygen atoms bind to the P-loop and assumes a trigonal bipyramidal geometry in both transition state analogue structures, with very similar apical O-O distances, binding structure, overview
VO3N3
-
oxovanadium(IV) is coordinated with one nitrogen and two oxygen atoms from the Schiff base and two nitrogen atoms from the bidentate planar ligands, in a distorted octahedral geometry, VO3N3
Zn2+
-
75.2% inhibition at 5 mM
Zn2+
-
Zn2+ inhibits the enzyme irreversibly in a concentration-dependent manner
Zn2+
-
strong inhibition
[(1-benzyl-1H-indazol-5-yl)(difluoro)methyl]phosphonic acid
-
-
[(2-benzyl-2H-indazol-5-yl)(difluoro)methyl]phosphonic acid
-
-
[(4-bromophenyl)(difluoro)methyl]phosphonic acid
-
-
[(4-[(4E)-2-(1H-benzotriazol-1-yl)-2-[4-(methoxycarbonyl)phenyl]-5-phenylpent-4-en-1-yl]phenyl)(difluoro)methyl]phosphonic acid
P30304, P30305, P30307
-
[(4-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
-
-
[(4-[[4-bromo-3,5-bis(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
-
selectivity with different PTPs, overview
[(4-[[4-bromo-3-(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
-
-
[(4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl]phenyl)(difluoro)methyl]phosphonic acid
-
-
[(BzMeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[(MeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[(MeMeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[(p-MeBzMeIm)Au(I)Cl]
Yersinia enterolytica
-
-
[4-[(2E)-3-(5-bromo-4-hydroxy-2-methoxyphenyl)prop-2-enoyl]phenoxy]acetic acid
-
-
[biphenyl-4-yl(difluoro)methyl]phosphonic acid
-
-
[difluoro(4-nitrophenyl)methyl]phosphonic acid
-
-
[difluoro(4-[[2-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
-
[difluoro(4-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
-
[difluoro(4-[[4-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
-
[difluoro(4-[[4-fluoro-3-(trifluoromethyl)phenyl]carbamoyl]phenyl)methyl]phosphonic acid
-
-
[difluoro[3-(phenylcarbamoyl)phenyl]methyl]phosphonic acid
-
-
[difluoro[4-(1,3-thiazol-2-ylcarbamoyl)phenyl]methyl]phosphonic acid
-
-
[difluoro[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl]phosphonic acid
-
-
[difluoro[4-(methylcarbamoyl)phenyl]methyl]phosphonic acid
-
-
[difluoro[4-(phenoxymethyl)phenyl]methyl]phosphonic acid
-
-
[difluoro[4-(phenylcarbamoyl)phenyl]methyl]phosphonic acid
-
-
[difluoro[4-(phenylsulfamoyl)phenyl]methyl]phosphonic acid
-
-
[difluoro[4-(propan-2-ylcarbamoyl)phenyl]methyl]phosphonic acid
-
-
[RuIII(EDTA)(OH2/OH)]1-/2-
-
RuIII-EDTA inhibits PTP, like vanadate, through an oxidant-independent pathway. It inhibits PTP at physiological pH values by a mechanism that involves binding of the Cys residue of the catalytic domain of the enzyme, overview. At pH 7.4, the Ru-EDTA complex exists as a mixture of aqua and hydroxo-species. The inhibition is reversible or inhibited by glutathione
-
[[4'-(2-butyl-1-benzofuran-3-yl)biphenyl-4-yl]oxy]acetic acid
P24666
-
[[4-(1H-benzimidazol-2-ylcarbamoyl)phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-(benzoylamino)phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-(benzylcarbamoyl)phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-([[3,5-bis(trifluoromethyl)phenyl]carbamoyl]amino)phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-[(1-ethylpiperidin-4-yl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-[(2-bromophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-[(2-chlorophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-[(3-bromophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-[(3-chlorophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-[(4-bromophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
-
[[4-[(4-chlorophenyl)carbamoyl]phenyl](difluoro)methyl]phosphonic acid
-
-
additional information
-
overview, development of inhibitors
-
additional information
-
overview on recently developed inhibitors
-
additional information
-
not inhibitory: okadaic acid
-
additional information
Q6JHV2
not inhibitory: pentamidine, okadaic acid, sodium fluoride up to 5 mM, EDTA up to 10 mM
-
additional information
-
in absence of externally added Ca2+, no effect of ethylene glycol bis(2-amino-ethylether) N,N,N,N-tetracetic acid or trifluoperazine. Not inhibitory: okadaic acid
-
additional information
-
inhibition data for isoforms CD45, Cdc25A, VHR; not inhibitory to PTP1B, CD45: disodium 3-(((4-methyl-3-(((2-methyl-5-((3-sulfonatophenyl)carbamoyl)phenyl)carbamoyl)amino)phenyl)carbonyl)amino)benzenesulfonate
-
additional information
-
enzyme is active in unstimulated or thrombin-stimulated platelets. Enzyme is not active in lysate of platelets adherent to fibrinogen
-
additional information
-
down-regulation of enzyme activity with small molecule inhibitors suppresses cell spreading and migration to fibronectin, increases Y527 phosphorylation in Src, and decreases phosphorylation of focal adhesion kinase, p130 Crk-associated substrate, and extracellular signal-regulated kinase 1/2
-
additional information
-
EDTA, sodium tartrate, sodium fluoride, or okadaic acid have no effect on activity
-
additional information
-
the presence of the superoxide- and hydrogen peroxide-destroying enzymes superoxide dismutase and catalase has no effect on the rate of the inactivation reaction
-
additional information
-
tert-butyl hydroperoxide cumene hydroperoxide do not inactivate PTP1B, 150 nM H2O2 has no measurable effect on enzyme activity
-
additional information
-
inhibition of PTP-PEST by RNAi reduces formation of podosomal structures at the cell periphery and reduces bone resorption indicating a positive functional role for this PTP in promoting osteoclast activity
-
additional information
-
3alpha,24,29-trihydroxyolean-12-en-28-oic acid, 3alpha,19alpha-dihydroxyurs-12,20(30)-dien-24,28-dioic acid, and 3alpha,19alpha-dihydroxyurs-12-en-24,28-dioic acid show very weak inhibitory effect towards PTP1B
-
additional information
-
beta2AR stimulation on a B cell phosphorylates and inactivates HePTP in a Gs/cAMP/PKA-dependent manner
-
additional information
-
not inhibited by costunolide, 11beta,13-dihydrocostunolide, reynosin, 1beta-hydroxy arbusculin A, santamarine, alpha-costol, beta-sitosterol, aplotaxene, and alpha-amyrin stearate
-
additional information
-
no inhibition by EDTA at 1 mM
-
additional information
-
structure derivatives, derived from papaverine, e.g. Pnu177496, in docking simulations, simulated molecular docking method, overview
-
additional information
-
synthesis and inhibitory activity of 38 synthetic chalcones towards PtpA, the predominant factor for the activity is the molecule planarity/hydrophobicity and the nature of the substituents, structure-activity analysis, overview. No inhibition by 3a, 3b, 3c, 4h, 5l, 6d, 6g, and 6j
-
additional information
-
inhibitor synthesis, inhibitor selectivity for PTP1B over TCPTP, overview
-
additional information
-
inhibitor synthesis, structure-activity relationships, overview
-
additional information
-
inhibitor docking studies with PTP-1B, overview
-
additional information
-
interaction between the alpha-cytoplasmic tail of a1beta1 integrin and TCPTP activates TCPTP by disrupting an inhibitory intramolecular bond in TCPTP, screening of screened 64280 small molecules for TCPTP inhibition, overview
-
additional information
-
the inhibition mechanism of [RuIII(EDTA)(OH2/OH)]1-/2- shows similar interactions, that may be important in the anti-cancer properties of the active forms of many Ru pro-drugs
-
additional information
-
structure-based optimization of benzoic acids as inhibitors of PTPB1 and LMW-PTP, molecular docking study using crystal structures of PTPB1, PDB ID 1G7G and 1XBO, as templates, overview
-
additional information
-
hyperosmotic stress inhibits PTP3. Overexpression of a dominant inhibitor of PTP3 leads to constitutive tyrosine phosphorylation and ectopic nuclear localisation of STATc
-
additional information
-
synthesis of series of oxovanadium complexes with mixed ligands, a tridentate ONO-donor Schiff base ligand with salicylidene anthranilic acid, and a bidentate NN ligand, e.g., 2,2'-bipyridine, 1,10-phenanthroline, dipyrido[3,2-d:2',3'-f]quinoxaline, dipyrido[3,2-a:2',3'-c]phenazine, or 7-methyldipyrido[3,2-a:2',3'-c]phenazine, spectroscopical analysis, and crystal structures of complexes bound to PTPB1, molecular modeling, overview
-
additional information
-
mechanism of substrate selectivity of five bidentate inhibitors, NNY, B07, F6Z, Q1M, and PYN, for PTP1B, compared to SHP-2 and TCPTP, using molecular dynamics simulations and free energy calculations, and crystal structures with PDB IDs 1NNY, 2B07, 2F6Z, 1Q1M, and 1PYN, 1L8k, and 2SHP, overview. Residues Arg24, Arg254, and Gln262 in the second binding site of PTP1B are essential for the high selectivity of inhibitors
-
additional information
-
inhibitory potency of gold(I) complexes containing N-heterocyclic carbene ligands versus cysteine-dependent protein tyrosine phosphatases, reversible inhibition, overview
-
additional information
Yersinia enterolytica
-
inhibitory potency of gold(I) complexes containing N-heterocyclic carbene ligands versus cysteine-dependent protein tyrosine phosphatases, reversible inhibhition, overview
-
additional information
-
bis(thiosemicarbazonato) metal complexes, e.g. with Cu2+ or Zn2+, inhibit PTP and its dephophorylating and inhibitory activity on the epidermal growth factor receptor, EGFR
-
additional information
-
PTP bidentate inhibitor library synthesis and screening, overview. The bidentate inhibitors have three components: 1. the warheads, alkyne-containing N-phenyloxamic acids that are cell-permeable, potent bioisosteric phosphotyrosine mimics, 2. a variety of different types of building blocks that act as the secondary-site binders, and 3. azide-containing linkers of different lengths joining the warhead and the building blocks, overview
-
additional information
-
the substitution of prenyl groups on pterocarpans might be important for in vitro PTP1B inhibitory activity, and hydroxyl group attached to C-6a or an aldehyde group attached to C-8 may decrease this activity. No inhibition by erylysins C, i.e. 8-formyl-3,9-dihydroxy-4,10-diprenylpterocarpan, by cristacarpin, and by erystagallin C
-
additional information
-
development of a rapid high-throughput screening method for PTP inhibitors, overview
-
additional information
-
design, synthesis and evaluation of a series of bromo-retrochalcones as PTP1B inhibitors based on licochalcone A and E, overview
-
additional information
-
design of structure based cyclic peptide inhibitors, synthesis involves a crucial intramolecular transamidation via a ring opening reaction. All the compounds show moderate to good inhibitory activities against MPtpA in micromolar concentrations, enzyme docking study, overview
-
additional information
-
the enzyme activity is diminished by increasing acetate buffer ionic strength, but PTP-H2 is unaffected by tetramisole and levamisole, as well as by okadaic acid, sodium fluoride and sodium citrate
-
additional information
-
inhibitor design using the crystal structure of PtpA, overview
-
additional information
-
unaffected by EDTA
-
additional information
-
unaffected by EDTA
-
additional information
-
unaffected by okadaic acid
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
1,2-epoxy-3-(p-nitrophenoxy)propane
-
C215D mutant, not wild type
2,3-diphosphoglycerate
-
activation
2-mercaptoethanol
-
activation
2-mercaptoethylamine
-
activation
ADP
-
activation
ATP
-
activation
ATP
-
activation; allosteric activation
beta-mercaptoethanol
-
6% increase of activity at 20 mM
CaCl2
-
0.01 mM, significant enhancement of activity
Calmodulin
-
0.0025 to 0.005 mM, significant enhancement of activity
cysteine
-
dependent
dithiothreitol
-
7.4% increase of activity at 20 mM
dithiothreitol
-
activation
EDTA
-
activation
EDTA
-
activation
glutathione
-
activation
glutathione
-
reducing agent required
IGF-I
-
IGF-I stimulates p52shc phosphorylation, with a significantly greater increase in p52shc phosphorylation in the p66shc knockdown cells compared to control cells. Overexpression of p66shc impairs IGF-I-stimulated p52shc tyrosine phosphorylation
-
NaCl
-
activity against phosphotyrosine, optimal at 0.1 M
NaCl
-
activating up to 0.5 M
phorbol 12-myristate 13-acetate
-
enzyme gene is among the 10 genes with the largest increased in expression upon phorbol 12-myristate 13-acetate stimulation
polylysine
-
activation
protamine
-
activation
spermidine
-
activates isozyme TC45 via a mechanism similar to alpha1-cyt, i.e. integrin alpha1 cytoplasmic tail residues 1164-1179, molecular mechanism, overview. Spermidine inhibits serum-induced cell proliferation in a TC45-dependent manner, and regulates EGFR and PDGFRb signalling via TC45
spermidine
-
activation
spermidine
-
activation
spermidine
-
activation
spermine
-
activation
spermine
-
activation
spermine
-
no effect at 0.02-0.2 mM
sulfhydryl compounds
-
-
suramin
-
0.01 mM, about 30% increase in activity of isoforms PTPalpha, LAR
tetrasodium 2-(((2-(3-(((3-(5-((2,5-disulfonatophenyl)carbamoyl)-1H-benzimidazol-2-yl)phenyl)carbamoyl)amino)phenyl)-1H-benzimidazol-5-yl)carbonyl)amino)benzene-1,4-disulfonate
-
0.01 mM, up to 4.5 activation of isoform PTPalpha wild-type
Triton X-100
-
0.1%, 25-30% activation
UpA
-
uPA regulates SHP-2 phosphorylation, stimulates its catalytic activity and association with PDGFR-beta and with lipid rafts
Mitoxantrone
-
activates isozyme TC45 via a mechanism similar to alpha1-cyt, i.e. integrin alpha1 cytoplasmic tail residues 1164-1179, molecular mechanism, overview
additional information
-
activation of enzyme after treatment with platelet derived growth factor, overview
-
additional information
-
acetyl 11-keto-beta-boswellic acid induces SHP-1 both at transcriptional and translational level in a dose-dependent manner
-
additional information
-
interaction between the alpha-cytoplasmic tail of a1beta1 integrin and TCPTP activates TCPTP by disrupting an inhibitory intramolecular bond in TCPTP
-
additional information
-
formation of SHPS-1/SHP-2/Src/p52shc complex formation is essential for p52shc activity
-
additional information
-
inhibition of the WPD-loop can be used to potently and specifically turn on the activity of a biologically important tyrosine phosphatase, PTP-PEST
-
KM VALUE [mM]
KM VALUE [mM] Maximum
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
1.19
-
1-naphthyl phosphate
-
pH 7.5
1.88
-
1-naphthyl phosphate
-
pH 5.5
15
-
3,6-fluorescein diphosphate
P18031
mutant S295F, pH 6.3
19
-
3,6-fluorescein diphosphate
P18031
wild-type, pH 6.3
0.16
-
3-O-methylfluorescein phosphate
-
in 50 mM sodium acetate (pH 5.5), 80 mM NaCl, 10 mM dithiothreitol, and 20% glycerol, at 22C
0.02
-
4,6,8-trimethyl-2-oxo-2H-chromen-7-yl dihydrogen phosphate
-
isoform PTP1B, 37C, pH 6.9
0.115
-
4,6,8-trimethyl-2-oxo-2H-chromen-7-yl dihydrogen phosphate
-
37C, pH 6.9
0.156
-
4,6,8-trimethyl-2-oxo-2H-chromen-7-yl dihydrogen phosphate
-
isoform CD45, 37C, pH 6.9
0.953
-
4-methylumbelliferyl phosphate
-
pH 5.5
2.41
-
4-methylumbelliferyl phosphate
-
pH 7.5
0.0008
-
4-nitrophenyl phosphate
Q6JHV2
pH 7.5
0.00485
-
4-nitrophenyl phosphate
-
-
0.014
-
4-nitrophenyl phosphate
-
pH 7
0.064
-
4-nitrophenyl phosphate
-
pH 8
0.08
-
4-nitrophenyl phosphate
-
truncated enzyme b-PTP1B(DELTA321)
0.1
-
4-nitrophenyl phosphate
-
truncated enzyme PTP1B(DELTA321)
0.11
-
4-nitrophenyl phosphate
-
truncated enzyme b-PTP1B(DELTA299)
0.169
-
4-nitrophenyl phosphate
-
pH 5
0.28
-
4-nitrophenyl phosphate
-
pH 7.8, 18C
0.345
-
4-nitrophenyl phosphate
-
pH 8.0, presence of 1 mM Mn2+
0.38
-
4-nitrophenyl phosphate
P18031
wild-type, pH 6.3
0.38
-
4-nitrophenyl phosphate
-
-
0.42
-
4-nitrophenyl phosphate
Q64604
-
0.44
-
4-nitrophenyl phosphate
-
pH 9
0.45
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme I115F, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.46
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme I115L, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C; mutant enzyme I115M, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.48
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme V79I, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.51
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme L145A, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.53
-
4-nitrophenyl phosphate
-
mutant H44N, GST fusion protein
0.53
-
4-nitrophenyl phosphate
Q4JB88, -
pH 6.5, 70C
0.54
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant P181C
0.55
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme V85F, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.56
-
4-nitrophenyl phosphate
-
mutant enzyme D236A/Q314A, at 30C, in 0.15 M Bis-Tris, pH 6.0
0.58
-
4-nitrophenyl phosphate
-
wild-type, GST fusion protein
0.58
-
4-nitrophenyl phosphate
-
pH 5.5, 25C
0.59
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme L145V, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.6
-
4-nitrophenyl phosphate
-
pH 7.8, 25C
0.6
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme I115V, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C; mutant enzyme V85M, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.62
-
4-nitrophenyl phosphate
Q9S427
wild type enzyme, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.66
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme V79L, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.71
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme L145F, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.8
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme V85L, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.83
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme L145M, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
0.85
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant P181C/E187C
0.89
57.7
4-nitrophenyl phosphate
-
value strongly dependent on ionic strength and pH
0.892
-
4-nitrophenyl phosphate
-
pH 5.5
1.1
-
4-nitrophenyl phosphate
-
22C, pH 5.5
1.1
-
4-nitrophenyl phosphate
P18031
mutant S295F, pH 6.3
1.18
-
4-nitrophenyl phosphate
-
pH 7.8, 2C
1.2
-
4-nitrophenyl phosphate
-
pH 6.2, 37C, PtpA
1.3
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant G184C
1.31
-
4-nitrophenyl phosphate
-
mutant enzyme D236A, at 30C, in 0.15 M Bis-Tris, pH 6.0
1.4
-
4-nitrophenyl phosphate
-
isoform PTP1B, 37C, pH 6.9
1.5
-
4-nitrophenyl phosphate
-
pH 6.2, 37C, PtpB
1.9
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant P181C/P186C
2
-
4-nitrophenyl phosphate
-
-
2.1
-
4-nitrophenyl phosphate
-
pH 7
2.11
-
4-nitrophenyl phosphate
-
mutant enzyme Q314A, at 30C, in 0.15 M Bis-Tris, pH 6.0
2.3
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant E187C/S188C
2.4
-
4-nitrophenyl phosphate
-
pH 5.0
2.4
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme I307L, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
2.5
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant P186C; pH 7.0, 22C, wild-type enzyme
2.5
-
4-nitrophenyl phosphate
-
-
2.7
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant E187C; pH 7.0, 22C, mutant V185C
2.8
-
4-nitrophenyl phosphate
-
mutant 416AA, PTPalpha, 25C, pH 7.0
2.9
-
4-nitrophenyl phosphate
-
mutant 529AA, PTPalpha, 25C, pH 7.0; wild-type PTPalpha, 25C, pH 7.0
3
-
4-nitrophenyl phosphate
-
-
3.1
-
4-nitrophenyl phosphate
-
pH 7.0, 22C, mutant F183C; pH 7.0, 22C, mutant P186C/E187C
3.26
-
4-nitrophenyl phosphate
-
wild type enzyme, at 30C, in 0.15 M Bis-Tris, pH 6.0
3.5
-
4-nitrophenyl phosphate
-
-
4.01
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme I307A, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
4.5
-
4-nitrophenyl phosphate
-
pH 7.5, 22C, recombinant enzyme
4.6
-
4-nitrophenyl phosphate
-
mutant G496V, PTPalpha, 25C, pH 7.0
5
-
4-nitrophenyl phosphate
-
-
5.03
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme V79A, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
5.05
-
4-nitrophenyl phosphate
-
pH 7.5
6
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme I307F, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
6.01
-
4-nitrophenyl phosphate
Q72JF6
pH 3.8, 75C, recombinant enzyme
6.3
-
4-nitrophenyl phosphate
Q9S427
mutant enzyme I307M, in 50 mM MES-NaOH (pH 6.0), 2.5 mM MgCl2, at 5C
9.5
-
4-nitrophenyl phosphate
-
pH 7.0
12.7
-
4-nitrophenyl phosphate
-
isoform SynPPM3, pH 7.5, 37C
24
38
4-nitrophenyl phosphate
-
value for the PTPase domain
25
-
4-nitrophenyl phosphate
-
-
37.88
-
4-nitrophenyl phosphate
Q72JF6
pH 3.8, 30C, recombinant enzyme
148
-
4-nitrophenyl phosphate
-
value for the full length enzyme
0.0111
-
6,8-difluoro-4-methylumbelliferyl phosphate
Q16828, Q99956, Q9Y6W6
MKP-4, in 20 mM Tris-HCl (pH 8.0) containing 2 mM dithiothreitol
0.0173
-
6,8-difluoro-4-methylumbelliferyl phosphate
Q16828, Q99956, Q9Y6W6
MKP-3, in 20 mM Tris-HCl (pH 8.0) containing 2 mM dithiothreitol
0.0448
-
6,8-difluoro-4-methylumbelliferyl phosphate
Q16828, Q99956, Q9Y6W6
VHR, in 20 mM Tris-HCl (pH 8.0) containing 2 mM dithiothreitol; VHR, in 20 mM Tris-HCl (pH 8.0) containing 2 mM dithiothreitol; VHR, in 20 mM Tris-HCl (pH 8.0) containing 2 mM dithiothreitol
0.0795
-
6,8-difluoro-4-methylumbelliferyl phosphate
Q16828, Q99956, Q9Y6W6
MKP-5, in 20 mM Tris-HCl (pH 8.0) containing 2 mM dithiothreitol
2.6
-
AAAAApYRHRR
-
pH 7.4, temperature not specified in the publication, RPTPalpha
-
0.0228
-
acetyl-DADEpY-NH2
-
pH 5.5, 30C, PTP1B
0.0246
-
acetyl-DADEpY-NH2
-
pH 5.5, 30C, PTP1B, mutants R47V, D48N
0.0424
-
acetyl-DADEpY-NH2
-
pH 5.5, 30C, PTP1B, mutants M258C, G259Q
0.219
-
acetyl-DADEpY-NH2
-
pH 5.5, 30C, PTPalpha
1.1
-
acetyl-DADEpYL-NH2
P18031
pH 7.0, 30C, isoform PTPH1
1.84
-
acetyl-DADEpYL-NH2
P18031
pH 7.0, 30C, isoform PTP1B, mutant F182H
4.04
-
acetyl-DADEpYL-NH2